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1 Introduction 
 
1.1 L-Carnitine 
 
L-Carnitine (L-3-hydroxy-4-N, N, N – trimethylaminobutyrate) is a naturally 
occurring amino acid derivate with essential functions in intermediary 
metabolism.[1] Chemically it can be described as a water-soluble 
zwitterion.[2] Carnitine is synthesized from the two essential amino acids 
lysine and methionine. Lysine provides the carbon backbone whereas 
methionine supplies with 4-N-methyl groups.[3] 
 
CH3
N+
CH3
CH3 CH2 C COO
-
H
OH
CH2
 
 
 
Figure 1: L-Carnitine 
1.1.1 Sources and metabolism of L-Carnitine 
 
L-Carnitine can be considered as a “semi-essential” biological compound. 
Mammals are basically able to synthesize it, but most important source is 
nutritional uptake.[2] About 75% of total body L-carnitine derives from diet, 
whereas about 25% are produced endogenously. Mainly the kidneys are 
responsible for synthesis of L-carnitine, but also liver, heart, bone muscle 
and brain tissues are able to produce this compound.[4] 
Dietary L-carnitine uptake ranges from 1-15 µmol/kg bodyweight per day. 
Regular consumption of red meat leads to uptake of 6-15 µmol/kg whereas 
vegans and vegetarians acquire a maximum of 8 µM carnitine/kg 
bodyweight per day.[5] People strictly following a red meat lacking diet like 
vegetarians might use carnitine dietary supplements. In this case it has to 
be considered that supplementary L-carnitine shows a decreased 
bioavailabilty (14-18%). Dietary L-carnitine on the other hand has a 
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bioavailabilty of 54-87% depending on the carnitine-concentration in the 
meal [6]. This dietary part of the carnitine-pool is absorbed actively and 
passively across the membrane of enterocytes. Carnitine homeostasis is 
kept constant through this dietary uptake, minor endogenously synthesis 
and very effective renal absorption. [7] The whole physiological L-carnitine 
pool is made up of free L-carnitine and many different acylcarnitine-esters 
like acetyl-L-carnitine, propionyl-L-carnitine or long chain fatty acid 
carnitine-esters.[6]  
After entering the blood stream L-carnitine gets transported across the cell 
membrane by the transport protein OCTN2 (Organic Cation/Carnitine 
Transporter 2) or also called solute carrier family 22 member 5 SLC22A5 
[8]. This membrane protein, physiologically a uniporter, is expressed in 
several different tissues like skeletal muscle, kidney, heart and brain. 
OCTN2, as a sodium/carnitine co-transporter, has a high affinity for 
carnitine, but can also serve as a polyspecific Na+ independent cation 
uniporter. [9] 
OCTN2 is not only important for L-carnitine uptake into adipocytes and 
myocytes, it also plays a crucial role in reabsorption of organic cations and 
carnitine in the proximal tubulus of the kidney.[10]  
1.2 Mitochondrial carnitine shuttle system 
 
After entering the cells in muscles, fat tissue or brain, L-carnitine fulfils its 
manifold roles. One central function of L-carnitine is its key role as a 
cofactor for the transport of long-chain fatty acids prone for β-oxidation 
across the mitochondrial membrane. The network executing this process is 
called carnitine acyltransferase system or “carnitine shuttle system”. Within 
this network several transferases and translocases enable important steps 
of energy metabolism and homeostasis.  
Long-chain fatty acids are the main energy source for many tissues. These 
fatty acids are produced by lipolysis in adipocytes and can be transported 
through the blood system bound to albumin.[11] Special transport proteins 
mediate the transport across the plasma membrane of the fatty acids. [12] 
 10 
After entering the cell long-chain fatty acids are first bound to fatty acid 
binding proteins that are present in the cytosol.[13] Before long-chain fatty 
acids are introduced into metabolism (β-oxidation) or get stored or are used 
for building of triglyzerides for the plasma membrane - depending on tissue 
and demand - they have to get activated by conversion to acyl-CoA. This 
reaction is catalysed by long-chain co-enzymA synthethases (LCAS). [14] 
The next step in this cascade is the transport into the intermembrane space 
of the mitochondria. The mechanism of this step has not yet been defined 
and characterized enough. The opinion that fatty acids are able to pass the 
outer mitochondrial membrane by diffusion has not been confirmed.[13]  
Two different pathways have been proposed for this process, both 
depending on the orientation of the Carnitine-Palmitoyltransferases 1 
(CPT1) in the outer mitochondrial membrane. This enzyme catalyses the 
important conversion of acyl-CoA + free L-carnitine to acylcarnitine + free 
CoA. This step is the rate-controlling step of the whole “carnitine-shuttle 
system” and also β-oxidation.  
Originally it has been proposed that the catalytic domain of CPT1 faces the 
intermembrane space between outer and inner mitochondrial 
membrane.[15] This orientation would mean that the activated fatty acids 
would have to pass the outer mitochondrial membrane. 
In the meanwhile a different pathway has been proposed in which the 
orientation of CPT1 is directed to the cytosol. [16] This topology can be 
explained by the fact that the effective substrate of CPT1 is the complex of 
acyl-CoA and acyl-CoA binding protein (ACBP), which would be too large to 
be transported into the intermembrane space. [17] Further on the voltage 
dependent pore-forming molecule (VDAC) in the outer mitochondrial 
membrane is too small to transport long-chain acylcarnitine esters. [18] 
Recently it has also been shown that CPT1 forms a hexamer in vivo [19]. 
The diameter of the resulting pore would allow the passing of molecules of 
the size of palmitoylcarnitine indicating that CPT1 might also fulfil transport 
duties. [17]  
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The carnitine-acylcarnitine translocase (CACT), residing in the inner 
membrane catalyses the transport of long-chain acylcarnitines formed by 
CPT1 across the inner mitochondrial membrane into the matrix in exchange 
for L-carnitine. [20]  
Carnitine Palmitoyltransferase 2 (CPT2) is associated with the inner 
mitochondrial membrane facing the mitochondrial matrix. This enzyme 
reconverts the acyl-carnitineesters to its original conformation of acyl-coA 
and free L-carnitine. [13] These long-chain fatty acids can now be used for 
ATP production by β-oxidation and subsequent introduction of the 
generated acetyl-CoA into the TCA (tricarboxylic acid cycle). Free L-
carnitine gets again exported into the cytosol via CACT for another round of 
fatty-acid transport across the mitochondrial membrane.  
In the mitochondrial matrix another transferase is located. The Carnitine-
Acetyltransferase transfers acyl groups of different sizes from acyl-coA to L-
carnitine resulting in an acyl-carnitine-ester. [21] It defines the equilibrium 
between acetyl-CoA (+ free L-carnitine) and acetylcarnitine (+ free CoA) 
and therefore regulates the acetyl-CoA/CoA ratio.[22]  
 
 
Figure 2: Carnitine-Acyltransferase System (Flanagan et al, 2010) 
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Another carnitine transferases which itself is not active in mitochondria but 
in peroxisomes is the Carnitine Octanoyltransferases. It enables the 
transport of medium-chain fatty acids from peroxisomes to mitochondria 
through the conversion of acyl-CoA´s, shortened by peroxisomal oxidation, 
to acylcarnitine. [23]  
1.2.1 The members of the “Carnitine-Shuttle-System” – 
enzymology and genomics 
1.2.1.1 Carnitine Palmitoyltransferase 1 (CPT1) 
 
The basic enzymology of CPT1 (EC 2.3.1.21) has been described above. 
Mammals express three isoforms of CPT1, all localized on different 
chromosomes.[24, 25] CPT1a represents the liver isoform, which is also 
expressed in kidneys. CPT1b is called the “heart isoform” and is mainly 
expressed in cardiac and skeletal muscle. [17] These two isoforms have 
been known and characterized for many years. In 2002 a third isoform, 
CPT1c, mainly expressed in brain tissue, has been discovered. [25] This 
enzyme is specialized for neural tissue fatty acid oxidation. It is mainly 
localized in the endoplasmatic reticulum of neuronal cells. [26] CPT1c also 
seems to play an important role in central control of energy metabolism, 
since CPT1c deficient mice showed abnormalities in hepatic 
gluconeogenesis, weight gain and insulin resistance. [25] Overexpression 
of the neural specific CPT1c in the hypothalamus leads to increased food 
uptake in mice by antagonizing the anorectic effects of leptin. [27] 
Also the CPT1a isoform seems to be located not only to the outer 
mitochondrial membrane. It may also enable the transport of long-chain 
fatty acids into the endoplasmatic reticulum for the synthesis of 
triacylglycerol. [28] 
As already mentioned above CPT1 catalysis the rate-controlling step of 
fatty acid degradation. This step can be inhibited by malonyl-coA, a product 
of the acetyl-carboxylase during fatty acid anabolism. This enables the 
inhibition of fatty acid oxidation under conditions where synthesis is 
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needed.[23] The three isoforms of CPT1 show different affinities to malonyl-
coA. The liver-isoform (CPT1a) shows higher affinity to L-carnitine and 
lower affinity to malonyl-coA in contrast to the muscle form (CPT1b).[24] 
This provides the body the important possibility to control the fatty acid 
metabolism especially in the heart where both isoforms are expressed at 
different levels.[22] Affinity of the CPT1 isoforms to malonyl-coA also 
correlates with the pH enabling decreased fatty acid oxidation during 
acidosis. [29] 
1.2.1.1.1 Transcriptional regulation of CPT1a 
 
CPT1a transcription rate in liver is increased with high fat diet, during 
starvation and streptozotocin induced diabetes.[30] Also multiple hormones 
influence the expression of CPT1a like glucocorticoids, thyroid hormone 
(T3) and insulin. Insulin inhibits transcription whereas cAMP increases 
CPT1a expression.[31] Fatty acids and hyperlipidemic drugs like fenofibrate 
activate CPT1a expression via Peroxisome Proliferator Activated Receptor 
alpha (PPARα).[30] PPARα binds to PPRE (PPAR responsive elements) 
as a heterodimer with RXRα (Retinoid X Receptor). [32]  
An important cofactor for activation of PPAR regulated genes is the 
peroxisome proliferator activated receptor gamma coactivators 1 alpha 
(PGC-1α).[33,34] Coactivators are transcriptional regulators that bind to 
already DNA liganded proteins. They act as gene expression stimulating 
factors, histon modifiers and they mediate interaction to other transcription 
factors.[35] Thyroid hormone T3 for instance influences CPT1a gene 
expression via PGC-1α.[36] T3 induced different PCG-1α isoforms, which 
further on activate in cooperation with T3 CPT1a expression. [37] 
The promoter structure in the different model organisms is highly conserved 
with only small differences. The main difference is that the human CPT1a 
gene contains two alternate first exons (exon 1a and exon 1b) whereas the 
other organisms like rat and mouse only have one first exon. [38,39]. A 
TATA-less promoter regulates CPT1a expression. The proximal region of 
the promoter start is similar to other TATA less promoters with a GC- rich 
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region. Two SP1 (specifity protein 1) binding sites -21 to -27 and -100 to -
107 relative to the start site of transcription and one CCAAT box for binding 
of nuclear factor Y have been identified. These two factors are responsible 
for basal transcription levels of CPT1a [40]. cAMP induced transcription is 
mediated via a “multi responsive element” containing a cAMP responsive 
element and a DR1 motif. CREB (cAMP responsive element binding –
protein) and HNF4α (hepatic nuclear factor 4 alpha) bind to this element 
and mediate the effect of cAMP on CPT1a expression.[31]  
Long chain fatty acids also induce CPT1a expression.[30] Also PPARα and 
PPARγ coactivators (PGC-1α) activate CPT1a transcription [41]. The exact 
mechanism how these factors regulate CPT1a has been discussed in the 
last few years quite controversial. It is generally accepted that fatty acids 
activate gene expression via PPARα. This model has been strengthened 
after the analysis of PPARα knockout mice, which showed diminished 
induction of genes regulated by this factor, amongst those CPT1a. But 
publications in the last few years reported different mechanisms for fatty 
acid mediated CPT1a expression. Long chain fatty acids are also able to 
induce CPT1a transcription in a PPARα independent pathway. [42] But a 
fatty acid responsive element independent from PPARα has been localized 
in the first intron. This element is mainly induced by PCG-1α during 
fasting.[38] A PPARα dependent element, which mediates the CPT1a 
expression induced by long chain fatty acids and also during fasting, has 
been identified in the second intron. This pathway again is independent 
from PCG-α.[41] This duplex regulatory mechanism indicates the 
importance of CPT1a expression for energy homeostasis during fasting.  
 
 
Figure 3: Scheme of CPT1a promoter 
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1.2.1.1.2 Transcriptional regulation of CPT1b 
 
The CPT1b promoter structure is highly conserved throughout the different 
model organisms. At least two different regulative elements control CPT1b 
expression in humans and sheep as well as in rats and mice .One promoter 
region is located up to 330nt upstream the first exon, whereas the second 
one is a complex secondary structure downstream of the transcriptional 
start site. [43] 
CPT1b promoter is very similar to CPT1a and CRAT a TATA-less promoter. 
Basal transcription is mediated by SP1 (specificity protein 1) and an 
enhancer complex. The binding site of this enhancer has been localized to 
the first intron/exon of the rat CPT1b promoter. [44]  
A FARE (fatty acid response element) drives the fatty acid induced CPT1b 
expression, which has been mapped in rat and human promoters. 
Peroxisome Proliferator Factor α (PPARα) activates this element. [45, 46] 
PPARα forms heterodimers with the nuclear receptor retinoic X receptor α 
(RXRα). This FARE overlaps with a COUP-TF binding site [45], also an 
element which is highly conserved in mammalian CPT1b promoters. 
Further promoter elements found in the upper promoter are E-boxes, more 
SP1 sites and a SRF (serum response factor) site, which is known for 
regulation of CPT1b in rats in combination with GATA. [47] Further it has 
been shown that the deletion of the CA-box sequence CCACCC leads to 
drastic decrease of reporter gene expression. [47] 
 
 
Figure 4: Scheme of CPT1b promoter 
1.2.1.2 Carnitine/Acylcarnitine Translocase (CACT) 
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As described above the carnitine-acylcarnitine translocase is an integral 
inner mitochondrial membrane protein. It catalyses the mole-to-mole 
exchange of carnitine and acylcarnitine to transport long chain fatty 
moieties can be transported into the mitochondrial matrix. [13, 48] CACT is 
also located in peroxisomes. [13] The enzyme shows a very high affinity for 
carnitine and acylcarnitine, but very low affinity for other compounds of the 
fatty acid metabolism. This substrate specificity makes CACT an important 
regulator of carnitine levels in mitochondria and cytoplasm and explains 
also the severity of CACT deficiencies. [13] CACT can be inhibited by acyl-
D-carnitine, which therefore regulates fatty acid oxidation. [49] 
1.2.1.2.1 Transcriptional regulation of CACT 
 
CACT promoter is also lacking a TATA box. A DPE element at -18/-13bp 
proximal the first exon mediates binding of TFIID enabling basal 
transcription levels. [50] DNA microarray analysis indicated that CACT 
expression is regulated by PPAR alpha [51, 52] Various analysis of the 
human CACT promoter showed that a PPRE is present –105bp to -75bp 
proximal of the first exon. This PPRE shows response to fibrates, statines 
and 9-cis retinoic acids, which results in elevated CACT mRNA levels. [53]  
Further on Sp1 and FOXA2 sites, located at -237/-227bp respectively -300/-
290bp have been identified in the CACT promoter. Sp1 contributes to 
CACT transcription in various cell types and tissues, whereas FOXA2 only 
promotes CACT expression in hepatic cells. [54] 
In the murine CACT promoter sequence four putative PPRE have been 
identified at following positions: -808/-796bp, -580/-568bp, -332/-324bp and 
+45/+57bp relative to promoter start. PPARα and PPARδ are able to bind 
this specific PPRE (AGGTCAAAGGTCA) located in the first exon 
+45/+57bp in the 5’ UTR of the murine Cact gene up-regulating the 
transcription. [48] 
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Figure 5: Scheme of CACT promoter 
1.2.1.3 Carnitine Palmitoyltransferase 2 (CPT2) 
 
Carnitine Palmitoyltransferase 2 is a protein of the mitochondrial matrix, 
which is anchored to the inner mitochondrial membrane. It reverts the 
carnitine esters to their original compounds namely acyl-coA and free 
carnitine.[13] CPT2 is expressed as the same protein in all tissues of the 
body with no different splice variants. It also shows no sensitivity to 
malonyl-coA, meaning that this compound does not inhibit CPT2 and 
further no important regulative function in β-oxidation can be described for 
CPT2.[23]  
1.2.1.3.1 Transcriptional regulation of CPT2 
 
The human CPT2 promoter showed putative binding elements for the 
following factors after theoretical promoter analysis: a TATA box, a PPRE, 
a Sp1 binding site and also a binding site for the insulin upstream factor 1 
(IUF-1).[55] The PPRE element is inducible by PPARα/RXRα heterodimers 
and is further on modulated by the orphan receptors COUP-TFI and 
ERRα.[56] The murine CPT2 receptor in the contrary shows no TATA box 
but several Sp1 binding sites and a putative AP-1 binding cassette. [56, 57]  
PPARα also plays an important role in the transcription of this member of 
the “carnitine-shuttle system”, as data from DNA microarray with PPARα 
deficient mice show.[51] PPARα deficient mice lack the ability to up-
regulate CPT2 expression after administration of fibrates or during 
starvation in contrary to wild type mice. [58]  
A notable characteristic of the human CPT2 promoter is the sequence of 
the PPRE. This PPRE only contains one half proportion with a perfect 
consensus sequence (TGACCT). The second part of it is not matching the 
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previous accepted consensus sequence (GAGCAC). By chromatin 
immunoprecipitation PPARα binding to this sequence and functionality of 
this site has been shown.[51]   
 
Figure 6: Scheme of human CPT2 promoter 
1.2.1.4 Organic Cation/ Carnitine Transporter 2 (OCTN2) 
 
OCTN2 is a sodium ion-dependent cation transporter and the most 
important carnitine transporter in the plasma membrane. [8] Most adult 
tissues highly express OCTN2, including skeletal muscle, kidney, placenta, 
and heart.[59] This transporter regulates the carnitine pools within the cell. 
In the plasma a carnitine concentration of 50 µM is physiological. OCTN2 
allows the cell to reach millimolare carnitine concentrations in the 
cytoplasm. [60]  
1.2.1.4.1 Transcriptional regulation of the Organic Cation/ Carnitine 
Transporter 2 (OCTN2 or SLC22A5) 
 
PPARα is also involved in regulation of OCTN2 mRNA levels. 
Administration of fibrates leads to upregulation of OCTN2 gene expression. 
Additionally carnitine biosynthesis is also upregulated through PPARα 
agonists. This synergetic effect results in carnitine accumulation within the 
cell. [61, 62]  
The Octn2 promoter in rat hepatocytes shows sensitivity to PPARα-
agonists ciprofibrate and fenofibrate. Several imperfect PPRE were 
identified in the rat promoter, but the sequence mediating the PPARα 
induced upregulation of transcription has not been defined yet. [63]  
The murine Octn2 promoter is also regulated by PPARα via a PPRE in the 
first intron in mouse hepatocytes. It has been shown that PPARα binds as a 
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heterodimer with RXRα this element, but it can not be excluded that other 
PPREs are also contributing to the Octn2 expression after administration of 
a synthetic PPARα agonist like WY14,643.[64]  
OCTN2 in the tissue of the large intestine is regulated in a different way. 
Recent data suggest that OCTN2 in colon of mice and humans is rather 
modulated by PPARγ than by PPARα.[65]  
The administration of cisplatin leads to massive urinary loss of L-carnitine. 
This effect of cytostatic therapy is traceable to regulative deactivation of the 
transcription factor PPARα and subsequent down regulation of OCTN2 in 
the kidney. [66] 
 
 
Figure 7: Scheme of OCTN2 promoter 
 
1.2.1.5 Carnitine Acetyltransferase (CRAT) 
The Carnitine Acetyltransferase is mainly localized in the mitochondrial 
matrix, but can also be found in peroxisomes and the endoplasmatic 
reticulum. [67] CRAT regulates the equilibrium between short-chain acyl-
coA (mainly acetyl-coA) and CoA, and acyl-L-carnitine and free L-carnitine 
within the mitochondrial matrix. [68] The nomenclature suggests that this 
enzyme mainly catalyses the conversion of acetyl-coA and free L-carnitine 
to acetylcarnitine and free Co-A but the optimum acyl-chain length for 
CRAT is C4. [69] The fact that CRAT is not localized in the cytosol shows 
the importance of this protein for the equilibrium of Acetyl-CoA/Co-A within 
organells and cellular compartments. [22] 
CRAT is also important in cell cycle regulation and is necessary for the 
progression from G1 into S-phase. [21] Decreased CRAT activity has been 
connected with disorders of the nervous system like Alzheimer’s disease. 
[70] But regarding this hypothesis opposing data has also been published, 
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saying that carnitine acyltransferases like CRAT and CPT1 are not changed 
in Alzheimer’s disease. [71] 
Very low expression of CRAT has been connected with skeletal muscle and 
Purkinje cell degradation. [72] Also a connection between the 
pathophysiology of peripher vascular disease and low CRAT activity has 
been proposed. [73] 
1.2.1.5.1 Transcriptional regulation of Crat 
 
As DNA microarray analysis indicated that PPARα also plays a key role for 
the regulation of CRAT expression [51, 52] The central role of this nuclear 
receptor in fatty acid metabolism is depicted in the figure below, where 
genes which are induces by PPARα are listed.  
 
Figure 8: Central role of PPARα in fatty acid metabolism: DNA microarray defined PPARα responsive 
genes (from Rakhshandehroo M et al, 2007). 
 
Most knowledge about the murine Crat promoter is known from data 
produced in our lab. Aniko Ginta Pordes published in her diploma thesis 
that gene expression of the murine carnitine acetyltransferase (Crat) gets 
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upregulated in case of L-carnitine supplementation after initial carnitine 
deficiency. The responsible promoter region for this effect could be 
detected. Reportergene-assays located this region within (-342/+15) in 
relation to the transcription start. [74] 
 
Figure 9: Reportergene Assay constructs:  
The theoretical promoter analysis with bioinformatical tools like TESS and 
Patch several binding sites for regulating transcription factors could be 
identified. Analysing these elements with band shift assays revealed that a 
RXRα/RARγ element showed the strongest signals correlating with the “L-
Carnitine effect”.  
The figure below shows the results of the theoretical promoter analysis.  
 
HNF-beta (Foxa2)       
-435 TTTGTTTGTT TGTTTTGGTG AGGGGTGATG GAGGGAATAG GTATGGCAGC AGTATTCTTG CGGAGCAAGG 
   GR        GR 
-365 CCACCTGTCA TCTTCTTTGT GCATGCCTCC ACCCAAGCAA TCTGAGACAG TCCCCAGTCA ACAGTTGTGT 
       TREB       USF  (CREB TGACCG) 
-295 TCTCCTGCCA TTCCTAGAGT GACGTTCAAG GACACCAGTC AGACTTGAAC GCACGTGACC GCCTCGACAG 
        HES-1         RXR-alpha/RAR-beta   CREB 
-225 CTAAGGTGGC TTTCGGAGGC GGAGAGCACG AGCGGGACAG CGCCTACCGT TGTGACCCCG TGACGGGAGC  
                      SP1  
-155 CCAGCGCCGG GCTGCTAACA GCTGAGCTAG AGGTCCGTCT CCGCAAGCCC CGCCCTCTGC GGCCACTCCC  
                    SP1 
 -85 CGGCTTGGGC CCACCCCGAG ATCGGGGCGA GCGGCCGGGG ACTGCGAGCC ACCAAAGCTC CGCCCCGTGA 
 
 -15 GTCCTGCCCC ACCGGCAGCC CGCCGGGCCC GGTGGCCGCG GGGCCGCCTC TACGGCTAGC GGCAGTGACT   
 
  +1 CGGCGACCTT GAACC 
Figure 10: Theoretical promoter analysis performed with TESS (adapted from Ginta Pordes[74]) 
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1.3 The importance of Acetyl-CoA pools 
 
Mammalian cells contain sequestered acetyl-coA pools, which are 
functionally separated by intracellular membranes. The most important 
acetyl-coA pool is located in the mitochondrial matrix. There acetyl-coA 
depicts an important crossroad of metabolic pathways and fulfils important 
regulative functions between catabolic and anabolic processes.  
A very important metabolic control function of acetyl-coA is the change from 
catabolism to anabolism.[17] During longer periods of fasting neuronal cells 
and red blood cells are still depending on glucose as energy source. In liver 
gluconeogenesis allows the synthesis of glucose out of non-carbohydrate 
precursors like lactate, alanine, glutamine and glycerol. [75] The rate-
controlling step as depicted in Figure 11, is catalysed by the pyruvate 
carboxylase, which mediates the conversion of pyruvate to oxaloacetate. 
This step is allosterically induced by acetyl-coA and ATP.[76] So in liver 
cells, when high amounts of other energy sources are available, like fatty 
acids, the acetyl-coA pool and ATP levels are high and it is more likely that 
the conversion of pyruvate to oxaloacetate is catalysed and 
gluconeogenesis is induced than acetyl-coA gets introduced into the Krebs 
cycle.[77] Acetyl-coA also activates pyruvate dehydrogenase kinases, 
which phosphorylate the pyruvate dehydrogenase. Phosphorylated 
pyruvatedehydrogenase is inactive and further on the utilization of acetyl-
coA in TCA circle is blocked. Also during fasting the pyruvate 
dehydrogenase gets blocked by phosphorylation sparing the free carbon 
compounds for gluconeogenesis. [78] 
One aspect of the pathophysiology of Diabetes Mellitus Type 2 is 
characterized by increased glucose production through gluconeogenesis in 
liver as a consequence of excessive supply of energy sources as described 
above. [79] 
An imbalanced intra-mitochondrial acetyl-coA pool has also been 
connected with abnormalities of the energy metabolism of skeletal muscle 
in diabetic patients. Insulin seems to be unable to mediate the switch from 
lipid to glucose metabolism within the muscle leading to decreased glucose 
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utilization in the muscle cells. This can be explained by raised 
pyruvatedehydrogenase phosphorylation due to high acetyl-coA levels. [80] 
Also in terms of cardiomyopathy defect regulation of acetyl-coA pools has 
severe consequences. The uncoupling between glycolysis and 
gluconeogenesis, which is controlled by acetyl-coA, leads to accumulation 
of products like lactate and protons that contribute to decreased efficiency 
of actin and myosin in the ischemic heart. [80] 
 
 
Figure 11: Central role of Acetyl-CoA  in fatty acid and glucose metabolism in the liver (abbrevations: PC 
–pyruvate carboxylase, PDH pyruvate dehydrogenase, PDHK – pyruvate dehydrogenase kinase) from 
Zammit et al, 2009.  
 
1.4 Medical and pharmacological aspects of L-Carnitine 
1.4.1 Carnitine deficiencies 
 
Defective fatty acid degradation has quite a big field of consequences. 
During fasting periods fatty acids are the main source of energy, but if this 
part of metabolism is defect, fatty acids accumulate in liver, skeletal and 
heart muscle. In liver inability of fatty acid catabolism leads to steatosis and 
decreased production of ketone bodies. During fasting brain tissue needs 
this ketone bodies as a consequence of glucose deficiency leading on the 
long run to loss of consciousness. Missing fatty acid degradation also leads 
do decreased acetyl-coA levels in liver, which normally induces the enzyme 
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pyruvate carboxylase as starting reaction of gluconeogenesis. If this branch 
of energy metabolism is also missing glucose, oxidation takes place without 
regeneration due to lack of gluconeogenesis leading to hypoglycaemia and 
finally to loss of consciousness. Accumulation of long-chain fatty acids and 
acylcarnitine-esters in heart muscle tissue leads to alteration of electric 
activity of the conduction system of the heart and further on to arrhythmia 
and cardiomyopathy. In muscle cells this accumulation of intermediates of 
the fatty acid metabolism leads to myopathy, hypotension and 
myoglobinuria.[81]  
There are different deficiencies in the „carnitine-shuttle-system“, that can 
cause such symptoms. 
1.4.1.1 Primary Carnitine Deficiency 
Primary carnitine deficiency (OMIM 212140) is an autosomal recessive 
disorder caused by mutations in the SLC22A5 gene coding for the 
cation/carnitine transporter OCTN2. This mutation leads to decreased 
ability of carnitine uptake into the cell across the plasma membrane. The 
following urinary loss of L-carnitine results in low plasma carnitine levels. 
Patients carrying such a mutation in this transporter present mainly 
metabolic and cardiac symptoms. [82] 
The metabolic symptoms are almost observed in children under 2 years of 
age. These patients are lethargic and refuse eating. They show symptoms 
like hepatomegaly, hypoglycaemia and elevated CK (creatinin kinase). 
Treatment consists of intravenous administration of glucose. Without 
treatment primary carnitine deficiency would lead to coma and eventually 
death. [81] 
Cardiomyopathy as a consequence of defect OCTN2 is mostly observed in 
older patients. Symptoms are associated with hypotension, an enlarged 
heart and decreased ventricular ejection fraction. Heterozygote carriers of 
mutated OCTN2 present cardiac hypertrophy. [83] 
Diagnosis is confirmed via determination of plasma carnitine levels. 
Physiological carnitine levels in the plasma ranges between 25-50 µM, 
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OCTN2 deficient patients show free plasma carnitine levels below 5µM. To 
determine whether this low plasma carnitine level is caused by a defect 
OCTN2 transport protein activity is via a cell-based assay in fibroblasts. [84] 
Meanwhile analysis of OCTN2 is part of the newborn screening. 49 different 
mutations have been mapped within the SLC22A5 gene. Patients suffering 
from primary carnitine deficiency respond to dietary carnitine 
supplementation with high doses of 100-400 mg/kg/day. [81] 
1.4.1.2 Secondary Carnitine Deficiency 
Secondary deficiency of carnitine is characterized by increased excretion of 
carnitine in urine in form of acylcarnitine as a consequence of accumulating 
organic acids. [85] Secondary carnitine deficiency has many different 
causes: increased urinal loss of carnitine (Fanconi-Syndrom), 
pharmacological therapy with agents like pivampicillin or valproic acid [86], 
different inherited metabolic disorders (discussed below), haemodialysis, 
and carnitine poor diet. [87] L-carnitine supplementation in patients 
suffering from secondary carnitine deficiency leads to normalized plasma 
carnitine levels and improvements in several symptoms and complications 
like cardiac problems, muscle symptoms and hypotension. [88] 
1.4.1.3 CPT-1 deficiency 
CPT-1 deficiency (OMIM 255120) is an autosomal recessive metabolic 
disorder. Hypoketotic hypoglycemia elevated free fatty acids and liver 
enzymes characterize this disease. Plasma carnitine levels are increased. 
Onset of this disease is usually between birth and the age of 18 month. [81, 
89] Children suffering from this disease show altered mental status and 
hepatomegaly. [81] 
1.4.1.4 CACT deficiency 
Deficiencies in the carnitine/acylcarnitine translocase (OMIM 212138) 
present metabolic misbalances like hypoketotic hypoglycemia especially 
after fasting periods, elevated creatinin kinases, hyperammonemia, very 
low free carnitine levels and elevated long-chain acylcarnitine 
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concentrations in the serum. Clinical symptoms comprise from seizures, 
irregular heartbeat and apnoea to skeletal muscle damage and 
cardiomyopathy. [81] A less severe type of CACT deficiency has been 
reported with delayed onset at the age of 15 month. [90] Since this disease 
is distinguishable from that caused by CPT2 deficiency only a fibroblast-
based assay of CACT activity can confirm the diagnosis.[91] Therapy 
consists of frequent feeding with carbohydrates, low fat, of which most 
should be of medium-chain length to be independent from the carnitine 
shuttle. Additional L-carnitine supplementation is strongly recommended. 
[81, 92] 
1.4.1.5 CPT-2 deficiency 
CPT2 deficiency (OMIM 255110) is the most common inherited disorder 
caused by a defect in the mitochondrial long-chain fatty acid oxidation. 
Three different types of this disease have been characterized; the most 
common of those is the myopathic from, which mainly occurs in young 
adults and shows symptoms of rhabdomyolysis provoked by exercise, 
fasting or fever. [93] The two other types are the infantile (OMIM 600649) 
and the neonatal lethal forms (OMIM 608836). [94] The neonatal type 
presents shortly after birth with seizures, hepatomegaly, cardiomegaly, 
cardiac arrhythmia and neuronal migration defects. The infantile form 
usually has its onset between 6 and 24 months of age and shows similar 
symptoms to CACT deficient patients. [81] Final diagnosis can be 
confirmed by DNA mutation studies and fibroblast-based CPT2 activity 
assays.  
Late-onset CPT2 deficiency is treatable with restriction of fat and long-chain 
fatty acids and increased dietary carbohydrate. Further on mild CPT2 
deficiency is treatable with fibrates. [81, 95]  
1.4.2 L-Carnitine and its analogues as pharmaceuticals in 
cardio-metabolic disorders 
 
The above-described deficiencies of proteins involved in fatty-acid 
metabolism underline the importance of L-carnitine and the acyl-carnitine 
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shuttle system. One common symptom of most deficiencies concerning this 
system is connected to cardiomyopathy.  
The first evidence for the therapeutic benefit of L-carnitine in the ischemic 
heart has been shown in pigs. [96] Especially propionyl carnitine leads to 
improved heart function after ischemia and heart failure. This can be 
explained by the fact that loss of L-carnitine takes place during ischemia. 
[97] Supplementation with L-carnitine in cases of ischemia and cardiac 
failure improves contractive function by modulating the acetyl-coA pool in 
the mitochondria by shifting the CRAT mediated reaction towards acetyl-L-
carnitine. [17] 
1.4.3 L-Carnitine and Diabetes Mellitus Type II 
 
Preclinical experimental data also reported a possible therapeutic effect of 
L-carnitine on diabetic conditions. In a study with streptozotocin-treated 
diabetic rats the administration of L-carnitine (3g/kg) over 6 weeks leads to 
significant decrease of plasma glucose levels. Also the reversal of the 
diabetes associated symptoms of polydipsia and glocosuria was 
observable.[98]  
A more recent study also showed the beneficial effect of L-carnitine on 
fructose induced diabetic metabolism in rats. The rat model was 
characterized by severe impairment of insulin sensitivity, increased hepatic 
gluconeogenesis, dyslipidemia and hyperglycemia. Administration of L-
carnitine intraperitoneally leads to normalization of glucose and insulin 
levels. The plasma values of free fatty acids and triglyzerides also 
normalized after L-carnitine administration. The rats returned to a diabetic 
metabolic state after withdrawal of supplementary L-carnitine.[99]  
1.5 PPAR-alpha and its regulative effect on fatty acid 
degradation  
 
Peroxisome proliferator-activated receptor alpha is a member of a 
subfamily of nuclear receptors. Together with other members of this 
subfamily (PPARγ and PPARδ) PPARα modulates signalling pathways of 
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intermediary metabolism and inflammation outlining the clinical importance 
of these nuclear receptors. [100] PPARα gets activated by derivatives of 
fibric acid (like fenofibrate and bezafibrate) and lowers triglyzerides and 
raises HDL (High density lipoproteins). [101] The PPARs are a family of 
liganded-activated receptors, which form heterodimers with RXR (retinoic X 
receptor) that bind to specific response elements (PPREs) to alter 
transcription levels of target genes.  
Polyunsaturated and saturated fatty acids are PPAR ligands. [102] Also a 
variety of other lipids have been identified as PPAR ligands like 
prostaglandins,[103] leukotrienes, acyl-CoA species. So far no endogenous 
PPAR ligand has been identified. 
PPARα expression takes place at high levels in liver cells where it 
promotes fatty acid oxidation, lipid transport and gluconeogenesis. [104] 
1.6 Goals of the project 
 
The previous results lead to the question which factor mediates the 
“Carnitine-effect” on the CRAT gene, meaning the upregulation of this 
gene. For this aim we wanted to repeat the theoretical promoter analysis 
with TESS and also new program called Patch, in order to include new 
findings gathered in the last few years in the field of transcription factors. 
This led us to a novel-binding site, namely a HNF-3β (FoxA-2). Further 
literature research also led us to the transcription factors PPARα and 
LXRα/β. These factors had to be tested via supershift assays.  
Another approach for identifying the transcription factor responsible for the 
L-carnitine response was found in southwestern-blotting. This technique 
allows estimating the size of a transcription factor binding to a specific site 
in a promoter. With further programs like “molwsearch” possible 
transcription factors can be determined.  
Another experimental approach was the measurement of RNA-levels via 
RT-Real Time PCR, in order to quantify the mRNA levels in cells, which 
were cultured under different metabolic and pharmacological conditions.  
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Here we wanted to investigate the effect of L-carnitine on transcriptional 
activity of the CRAT gene in course of time and also we wanted to test the 
effect of different concentrations of L-carnitine on CRAT transcription in the 
murine liver cell line TIB73.   
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2 Methods 
2.1 Cell culture 
 
All experiments were performed with TIB73 murine liver cells.  
2.1.1 Propagation of cells 
 
The cells were grown in 100mm petri-dishes with 10ml of Dulbecco´s 
modified Eagles´s medium (DMEM) supplemented with 10% foetal calf 
serum and 1% Antibiotics (30mg/l penicillin, 50mg/l streptomycin sulphate). 
Cells were grown at 37°C with 100%humidity and 7.5% CO2 near to 
confluence and were split in order to allow continuous growth. Cell splitting 
was performed after removal of the medium and incubation of the cells with 
6-7 drops of Trypsin/EDTA at 37° for some minutes. The de-attachment 
and mobilization of the cells was verified through observation under the 
microscope. The cells resuspended in 10ml DMEM+10%FCS and AB+G 
were counted in the CASEY-cell counter and seeded onto fresh 100mm 
petri dishes in desired density.  
2.1.2 Freezing of the cells 
 
Growing cells with a density of 2 million cells per petri dish were treated 
with Trypsin/EDTA to detach the cells from the petri dish. The cells were 
resuspended in 1.5ml DMEM+10%FCS+AB+G and transferred into a 1.8ml 
cryo-freezing tube. Afterwards 150µl of DMSO were added and the mixed 
with the cell suspension through inverting the tube. The cells were frozen at 
-80°C.  
2.1.3 Thawing of cells 
 
Frozen cells were slowly thawed on ice and finally transferred in a 100mm 
petri dish with 10ml of pre-warmed DMEM+10%FCS+AB+G and further on 
cultivated at 37°, 100%humidity and 7.5% CO2.  
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2.1.4 Metabolic conditions for cell cultivation 
 
For the band shift assays, supershift assays, southwestern blot analysis, 
western blot analysis nuclear extracts were prepared from TIB73 mouse 
liver cells cultured under different metabolic conditions.  
 Normal (N): TIB73 cells were grown in DMEM+10%FCS+Antibiotics 
+Glutamine until they reached confluence – meaning about 2-3 
million cells on a 100mm petri dish.  
 Starvation (St): TIB73 cells were grown in DMEM+0,5%FCS+Ab. 
Medium change had to be performed each day in order to offer 
essential nutrients.  
 Serum Induction (SI): at first TIB73 cells were grown in Starvation 
Medium (DMEM+0,5%FCS+Ab) for 2 days. Afterwards the cells got 
serum induced, by adding DMEM+20%FCS+Ab for 24 hours.  
 0µM-L-carnitine (dialysed FCS): TIB73 cells were grown in 
DMEM+10% FCS+AB+G for 24 hours. Afterwards these cells were 
cultivated in DMEM+ 10% dialyzed FCS+Ab+G 
 40µM-L-carnitine: TIB73 cells grown on medium with dialysed FCS 
got induced with 40µM-L-carnitine for a desired amount of time.  
 80µM-L-carnitine: TIB73 cells grown on medium with dialysed FCS 
got induced with 40µM-L-carnitine for a desired amount of time.  
 120µM-L-carnitine: TIB73 cells grown on medium with dialysed 
FCS got induced with 40µM-L-carnitine for a desired amount of time.  
 5µM-dexamethasone: TIB73 cells were grown till confluence 
reached 2/3 of the petri dish. These cells got supplemented with 
DMEM+10%FCS+Ab+G +5µM dexamethasone 
 10µM-dexamethasone: TIB73 cells were grown till confluence 
reached 2/3 of the petri dish. These cells got supplemented with 
DMEM+10%FCS+Ab+G +10µM dexamethasone 
2.1.5 Media and solutions for cell culture 
 
DMEM (Dulbecco´s modified eagle medium) +10% FCS and antibiotics:   
Powdered Dulbecco´s Modified Eagle Medium was dissolved in water 
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supplemented with 3,7g/l NaHCO3 and filtered using a sterile filter. DMEM 
(445ml) was supplemented with 5ml antibiotics (AB) and 50ml fetal calf 
serum (FCS, Gibco BRL). 
 
Dialyzed FCS 
Dialysis of FCS was performed against 1xPBS for 48 hours with 5 buffer 
changes.  
 
10xPBS 
80 g/l NaCl 
2 g/l KCl 
16.5 g/l Na2HPO4 
2 g KH2PO4 
adjust to pH 7.4 
2.2 Nuclear Extracts 
 
The isolation of nuclear extracts was performed after the protocol described 
from Siu et al.[105]   
1. Cells were cultivated on 100mm petri dishes till they reached 
confluence of 80-90%. 
2. Cells were washed 3 times with 1xPBS. 
3. Per dish 2ml of Cell Lysis Buffer were added.  
4. Cells were dislodged from the petri dish using a rubber policeman 
and afterwards transferred into a 2ml eppendorf tube.  
5. The cell suspension was centrifuged at 2,500g at 4°C for 5min.  
6. The supernatant was removed without disturbing the pellet.  
7. The pellet was resuspended in 500µl of Nuclear Extract Buffer and 
incubated at 4°C on a rocker platform (50 r.p.m) 
8. The cell debris was removed by centrifugation at 12,000g for 10 min 
at 4°C.  
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9. The supernatant containing the nuclear extracts was transferred into 
a new Eppendorf tube and quick frozen in liquid nitrogen and 
afterwards stored at -80°C.  
10.  Protein concentration was measured right before use.  
2.2.1 Bradford Assay 
 
In order to measure protein concentration Bradford concentrate got diluted 
1:5 with ddH2O. 2µl of the nuclear extract solution were added to 1ml 
Bradford diluent and incubated at room temperature for 5 minutes and 
absorbance was measured at 595nm. BSA protein standards (1µg-10µg) 
were used for quantification.  
2.2.2 Buffers and Solutions 
 
Cell Lysis Buffer:  
 
20 mM HEPES pH 7.6 
20 % Glycerol 
10 mM NaCl 
1.5 mM MgCl2 
0.02 mM EDTA 
0.1% Triton X 
1 mM  DTT 
 
Protease Inhibitors (Roche) and PMSF were added right before use.  
 
Nuclear Extract Buffer: 
 
20 mM HEPES pH 7.6 
20 % Glycerol 
500 mM NaCl 
1.5 mM MgCl2 
0.02 mM EDTA 
0.1% Triton X 
1 mM  DTT 
 34 
 
Protease Inhibitors (Roche) and PMSF were added right before use. 
2.3 Band Shift Assays 
 
For Band Shift analyses different ODN´s were designed:  
• SP1_2:  
 sense: 5' GCC ACC AAA GCT CCG CCC CGT GAG TC 3’ 
antisense: 5'GAC TCA CGG GGC GGA GCT TTG GTG GC 3’ 
 
• RXR/RAR: 
 sense: 5' CCT ACC GTT GTG ACC CCG TGA CGG G 3’ 
antisense: 5' CCC GTC ACG GGG TCA CAA CGG TAG G 3’ 
 
• HNFβ: 
 sense: 5' GTT TGT TTG TTT GTT TTG GTG 3’ 
antisense: 5' CAC CAA AAC AAA CAA ACA AAC 3’ 
 
• PPARα_1: 
 sense: 5' GGC ACC TTG AAC CTA GAA CCG 3’ 
antisense: 5' CGG TTC TAG GTT CAA GGT GCC 3’ 
 
• RXR_1: 
 sense: 5' AGC GCC TAC CGT TGT GAC CCC G 3’ 
antisense: 5' CGG GGT CAC AAC GGT AGG CGC T 3’ 
 
• Creb: 
 sense: 5' CGT GAC GGG AGC CCA GCG CCG G 3’ 
antisense: 5' CCG GCG CTG GGC TCC CGT CAC G 3’ 
 
• USF/CREB: 
 sense: 5' GAA CGC ACG TGA CCG CCT CG 3’ 
antisense: 5' CGA GGC GGT CAC GTG CGT TC3’ 
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For supershift analysis following antibodies were used:  
SP1: sc-420 
PPARα: sc-9000 X 
LXRα/β:sc-1201 X 
Nurr77: sc-7013 X 
Trap220: sc-74475 
PPARγ: sc-7273 
CREB: sc-186 X 
2.3.1 Labelling of oligonucleotide probe – Spun column method 
 
Oligonucleotides were marked radioactively with γ-32 phosphate by T-4 
polynucleotide kinase reaction (PNK reaction) 
 
Reaction mix:  
1 µl  Oligo desoxynucleotide (100ng/µl) 
5 µl 10x T4- polynucleotidkinase buffer 
4 µl γ-32 ATP 
1.5 µl T4-PNK 
38.5 µl ddH2O 
Ad 50 µl Total volume 
 
Reaction mix was incubated for 30 minutes at 37°C and stopped by 
addition of 50 µl of 1xTEN buffer. The whole reaction mix was transferred 
on spun column and centrifuged at 2.500rpm for 5 minutes.  
Before and after centrifugation 1µl of the radioactive reaction mix was 
mixed with 99 µl of dH2O and used for Cherenkov activity measurement to 
control the incorporation of γ-32 ATP.  
Afterwards 2-3 µl of asODN was added and heated to 90°C. For proper 
annealing the reaction mix was kept at room temperature for 30 minutes 
before storage at 4°C.  
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2.3.2 Reaction mix for band shift and supershift assay 
 
10 µl 2x Reaction Buffer 
1 µl Sonicated salmon sperm (5µg/ml) 
1 µl ssODN (γ-32 ATP) 
 x µl 10µg nuclear extract 
y µl ddH2O 
0.5-1-5 µl antibody solution 
Ad 20µl Total volume 
 
Reaction mix was incubated on ice in the dark for 30 minutes before 
loading the reaction mix onto an analytical non-denaturating polyacrylamide 
gel. Gel electrophoresis was performed at 100-120 V at 4°C in 1xTBE for 7-
8 hours.  
After electrophoresis the gel was transferred on Whatman paper, covered 
with PE foil and dried under vacuum for 2-4 hours and exposed to x-ray 
films for 24 hours up to 1 week.  
2.3.3 Band shift gel  
 
6.36 ml 30% Acrylamide-Bisacrylamide 
36.84 ml dH2O 
2.88 ml 10x TBE 
240 µl APS (10%) 
48 µl TEMED 
2.3.4 Buffers and solutions 
 
10x TBE (1000 ml) 
108 g TRIS  
55 g Boric acid 
40 ml EDTA (pH 8.0) 
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10x TEN 
0.1 M TRIS  
0.01 M EDTA (pH 8.0) 
1 M NaCl 
 
5x Binding Buffer 
20% glycerol 
100 mM TRIS-HCl pH 8.0 
300 mM KCl 
25 mM MgCl2 
500 µg/ml bovine serum albumine 
 
30% Acrylamide-Bisacrylamide (100ml) 
38 g acryl amide 
2 g bisacrylamide 
1 spoon Dowex 
Ad 100 ml ddH2O 
 
2.4 Southwestern Blotting 
 
This technique allows the determination of the molecular weight of factors 
binding to a specific oligonucleotide sequence. For this aim again ODN´s 
were labelled with radioactive γ-32ATP. The protocol for this experimental 
approach was obtained from Siu et al. [105] 
For southwestern analysis nuclear extracts were prepared as discussed 
above. First a denaturing SDS-page (10% SDS acrylamide gel) was 
performed to separate the proteins per size. Afterwards the proteins were 
transferred on to a nitrocellulose membrane by electro-blotting (wet blotting 
technique at 100 V at 4°C for 1 hour). For active binding of proteins to 
oligonucleotides proteins had to be renaturated. For this aim the 
nitrocellulose membrane was incubated with TNED buffer with 5% skim 
milk for 24 hours. The renatured membrane bound proteins were incubated 
 38 
with the radioactive γ-32labelled oligonucleotides of a specific DNA 
sequence in TNED buffer with 2.5% skim milk for 24 hours. After 3 washing 
steps with TNED buffer the blot was dried for some minutes at room 
temperature. The interaction is finally visualized via autoradiography.  
The comparison of the resulting signals with the molecular weight marker 
(PageRuler TM – Prestained Protein Ladder) on the original nitrocellulose 
membrane allows the determination of the weight of the protein marked by 
the γ-32labelled ODN. Subsequent use of the online program “molwsearch” 
from the website www.gene-regulation.com [106] allows the listing of 
possible transcription factors of a defined protein size.  
2.4.1 Buffers and Solutions 
 
10% SDS Separating Gel 
 
 
 
 
 
 
 
 
Stacking Gel 
dH2O 2,55 ml 
30% acrylamide 0,625 ml 
1 M Tris, pH 8.8 0,475 ml 
10% SDS 37,5 µl 
10% APS 37,5 µl 
Temed 2,5 µl 
 
dH2O  2,03 ml 
30% acrylamide 2,5 ml 
1 M Tris, pH 8.8 2,81 ml 
10% SDS  75 µl 
10% APS  75 µl 
Temed 7,5 µl 
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1x TNED Buffer 
10 mM TRIS HCl pH 7.5 
50 mM NaCl 
0.1 MM  EDTA pH 8.0 
1mM  DTT 
 
5x Western Blot Running Buffer 
100 mM TRIS  
1 M glycine 
1.2%  SDS 
 
1x Western Blotting Buffer 
25 mM TRIS  
190 mM glycine 
20%  methanol 
 
2.5 Western Blot 
 
For protein analysis 20µg of nuclear proteins were mixed with sample buffer 
and incubated at 95°C for 5 minutes. Samples were loaded on a 10% SDS 
polyacrylamide gel (SDS-PAGE). For orientation and size determination a 
prestained molecular weight marker was loaded.  Electrophoresis was 
performed at 120V. Afterwards proteins were transferred onto a 
nitrocellulose membrane with wet blot technique. (250 mA for 2.5 hours).  
Membranes were blocked after transfer with 1xPBS-T containing 5% skim 
milk at room temperature for at least one hour. Depending on 
manufacturers protocols primary antibody solution was prepared (1:100 up 
to 1:1000). Incubation of the blot with primary antibody was performed 
overnight at 4°C followed by 3 washing steps with 1xPBS-T. The blot was 
incubated with a 1:10.000 secondary antibody solution (HRP-conjugated 
secondary antibody) for at least one hour at RT and subsequently the blot 
was washed again 3 times with 1xPBS-T. For detection ECL solution was 
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prepared fresh as a 1:1 mixture of the two ECL solutions (Perkin Elmer Life 
Science). The blot was incubated with ECL solution for 2 minutes, followed 
by removal of the solution. The blot got exposed to radio films for various 
amounts of time (from 1 minute to 1 hour).  
2.5.1 Buffers and solutions 
 
Running buffer and transfer buffer were prepared as described for 
southwestern blotting.  
 
Antibody:  
For PPARα Western Blots sc-9000 anti-PPARα antibodies by Santa Cruz 
Biotechnology were used. Best results were obtained with a ratio of 1:500.  
 
Sample buffer.  
30 mM TRIS HCl pH 6.8 
30% glycerol 
10% SDS 
1mM DTT 
0.002% bromophenol blue 
 
Blocking Solution 
1x PBS 
0.1% Tween 20 
5% skim milk (powder) 
 
2.6 RT-Real Time PCR 
2.6.1 Cell Culture 
2.6.1.1 Propagation of cells 
The cells were grown in 100mm petri-dishes with 10ml of Dulbecco´s 
modified Eagles´s medium (DMEM) supplemented with 10% foetal calf 
serum and 1% Antibiotics (30mg/l penicillin, 50mg/l streptomycin sulphate). 
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Cells were grown at 37°C with 100%humidity and 7.5% CO2 near to 
confluence and were split in order to allow continuous growth. Cell splitting 
was performed after removal of the medium and incubation of the cells with 
6-7 drops of Trypsin/EDTA at 37° for some minutes. The de-attachment 
and mobilization of the cells was verified through observation under the 
microscope. The cells were resuspended in 10ml DMEM+10%FCS + 
Ab+G, counted in the CASEY-cell counter and seeded onto fresh 100mm 
cell culture-dishes in desired density.  
2.6.1.2 Metabolic conditions for cell cultivation 
For the real-time analysis mRNA was isolated from TIB73 mouse liver cells 
cultured under different metabolic conditions.  
 Normal (N): TIB73 cells were grown in DMEM+10%FCS+Antibiotics 
+Glutamine until they reached confluence – meaning about 2-3 
million cells on a 100mm petri-dish.  
 Starvation (St): TIB73 cells were grown in DMEM+0,5%FCS+Ab 
Medium change had to be performed on a daily basis in order to 
offer essential nutrients.  
 Serum Induction (SI): at first TIB73 cells were grown in Starvation 
Medium (DMEM+0,5%FCS+Ab) for 2 days. Afterwards the cells got 
serum induced, by adding DMEM+20%FCS+Ab for 24 hours.  
 10µM fenofibrate: normal grown cells (DMEM+10%FCS+Ab) were 
cultured till the requested density. Afterward these cells were 
supplemented with 10µM fenofibrate for 3 hours before harvesting.  
 20µM fenofibrate: normal grown cells (DMEM+10%FCS+Ab) were 
cultured till the requested density. Afterward these cells were 
supplemented with 20µM fenofibrate for 3 hours before harvesting.  
 40µM fenofibrate: normal grown cells (DMEM+10%FCS+Ab) were 
cultured till the requested density. Afterward these cells were 
supplemented with 40µM fenofibrate for 3 hours before harvesting. 
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 0.5µM LXR agonist: normal grown cells (DMEM+10%FCS+Ab) 
were cultured till the requested density. Afterward these cells were 
supplemented with 0.5µM GW3965 for 3 hours before harvesting. 
 1µM LXR agonist: normal grown cells (DMEM+10%FCS+Ab) were 
cultured till the requested density. Afterward these cells were 
supplemented with 1µM GW3965 for 3 hours before harvesting. 
 1.5µM LXR agonist: normal grown cells (DMEM+10%FCS+Ab) 
were cultured till the requested density. Afterward these cells were 
supplemented with 1.5µM GW3965 for 3 hours before harvesting. 
 5µM retinoic acid: normal grown cells (DMEM+10%FCS+Ab) were 
cultured till the requested density. Afterward these cells were 
supplemented with 5µM retinoic acid for 3 hours before harvesting. 
 10µM retinoic acid: normal grown cells (DMEM+10%FCS+Ab) were 
cultured till the requested density. Afterward these cells were 
supplemented with 10µM retinoic acid for 3 hours before harvesting. 
 15µM retinoic acid: normal grown cells (DMEM+10%FCS+Ab) were 
cultured till the requested density. Afterward these cells were 
supplemented with 15µM retinoic acid for 3 hours before harvesting. 
2.6.2 RNA-Isolation 
 
RNA isolation was performed with the GeneJet RNA Purification Kit by 
Fermentas according the manufacturers protocols with small modifications: 
 
 Growth medium was removed  
 Cells were washed with 1xPBS followed by aspiration of PBS 
 The cells were rubbed off with a rubber policemen in an adequate 
amount of PBS and transferred into a Eppendorf tube 
 Cells were centrifuged at 1300 rpm for 5min 
 Supernatant got discarded 
 Pellet was resuspended in 600µl Lysis Buffer 
 Cell suspension was vortexed for 10sec until it is well homogenized 
 360µl of 96% EtOH were added and mix sample by pipetting 
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 Up to 700µl of lysate were transferred to the Purification Column 
inserted in a collection tube 
 This step was repeated until all of your lysate had been transferred 
into the column 
 Flow-through was discarded and the purification column was placed 
the on a new collection tube (2ml) 
 700µl of Wash Buffer 1 were added  
 Centrifugation with 10.000 rpm for 1’ 
 Flow-through was discarded 
 600µl of Wash Buffer 2 were added  
  Centrifugation with 10.000 rpm for 1’ 
 200µl of Wash Buffer 2 were added 
 Centrifugation with 10.000 rpm for 2’ 
 Purification column got transferred to microcentrifuge tube  
 50µl of nuclease free water were added 
 Centrifugation at 10.000 rpm for 1’ 
 RNA concentration was measured with NanoDrop photometer and 
stored at –80° 
2.6.3 cDNA Synthesis 
 
cDNA synthesis was performed after manufacturers protocols with the 
Revert Aid M-MuLV Reverse Transcriptase Kit: 
3µg of RNA and 1µl of oligo dT-primers were added to DEPC treated water 
to a volume of 11µl. Subsequently the samples were heated to 70°C for 5 
minutes followed by incubation on ice for another 5 minutes. In the next 
step 4µl of 5x reaction buffer by Fermentas, 2µl of dNTP mix (10mM stock), 
1µl of RNase Inhibitors (Fermentas) and 1µl of DEPC treated water were 
added and incubated at 37°C for 5 minutes. Afterwards 1µl of Reverse 
Transcriptase (by Fermentas) was added and incubated at 42°C for 1 hour.  
The enzyme got deactivated afterwards by heating the samples to 70°C for 
1 minute followed by an additional incubation on ice for 4 minutes. Samples 
were stored until use at -80°C.  
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2.6.4 Primers 
 
Primers for PCR were designed by use of the web tool “Primer3”. 
 
muβ-Actin: 
sense  5'- GCGTGACATCAAAGAGAAG -3' 
antisense  5'- AGGAGCCAGAGCAGTAATC -3' 
Ta: Block-PCR 52°C, RT-PCR 55°C. 
 
muCRAT: 
sense  5'- GCTCAGCCTCCATAGACTCG -3' 
antisense  5'- AGCAATGGCGTAAGAGGTGT -3' 
Ta: Block-PCR 52°C, RT-PCR 55°C. 
 
muCPT1a: 
sense  5'- CCAGGCTACAGTGGGACATT -3' 
antisense  5'- GAACTTGCCCATGTCCTTGT -3' 
Ta: Block-PCR 50°C, RT-PCR 53°C. 
 
muCACT: 
sense  5'- TGGACACTGTTGCTGAGAGG -3' 
antisense  5'- TTGGCCAAAGGTATCGAGTC -3' 
Ta: Block-PCR 52°C, RT-PCR 55°C. 
 
muOCTN2: 
sense  5’- ACAGTATCCCGTTCGACACG -3’ 
antisense 5’- ACACCAGGTCCCAGTCTGTC -3’ 
Ta: Block-PCR 52°C, RT-PCR 55°C. 
 
muCPT2 
sense  5’- TCCTCGATCAAGATGGGAAC -3’ 
antisense 5’- GATCCTTCATCGGGAATCA -3’ 
Ta: Block-PCR 52°C, RT-PCR 55°C. 
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2.6.5 Block PCR and gel extraction 
 
Classic block PCRs on gradient cyclers were performed with each designed 
primer-pairs in order to check their specifity and reactivity. After gel 
electrophoresis the PCR products were cut out of the gel, extracted after 
the manufacturer’s protocol with the “Concert Gel Extraction System” by 
Gibco BRL and DNA concentration was measured. From this “DNA-stocks” 
defined DNA concentrations were diluted from 1µg/µl down to 1ag/µl as 
standards for the following real-time PCR.  
2.6.6 Real-Time PCR 
 
Real-Time PCR was performed based on LightCycler Fast Start DNA 
Master SYBR Green I. 
2.6.6.1 Pipetting scheme for RT-PCR and protocol for Roche Capillary 
LightCycler  
The following scheme depicts the volumes for one LightCycler reaction. 
LightCycler capillaries were precooled at 4°C in centrifuge adapters.  
 
 The following components were prepared. Depending on number of 
reactions the amounts were multiplied and prepared as a mastermix 
in a 1.5ml eppendorf tube.  
10.2µl ddH2O 
1,3µl MgCl2 
0.5µl primer sense 
0.5µl primer antisense 
1.5µl SYBR Green 
Master Mix 
 
 Components were gently mixed 
 14 µl of the mastermix were pipetted into the precooled capillaries 
 1µl of the sample cDNA was added 
 The capillaries got sealed with a stopper  
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 Together with the precooled adapter the capillaries got placed in a 
microcentrifuge and spun down 
 The capillaries were placed in the rotor of the LightCycler and the 
run was started 
 
For each tested gene the annealing temperature was first optimised on a 
gradient cycler. For each gene a standard curve was obtained using the 
LightCycler. cDNA samples were diluted 1:100 right before use. All samples 
were measured at least in triplicates. The mean of these measurements 
was normalized to the housekeeping gene β-actin, which itself was 
measured three times. The RT-PCR results are based on relative 
quantification. [107] 
 
2.6.7 Statistical Analysis 
 
Continuous data was presented as mean and standard deviation. 
Differences between groups were assessed by means of impaired Students 
T-Test. Statistical analysis was performed with SPSS Statistics 17.0 (IBM, 
Armonk, USA). 
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3 Results 
3.1 Results of the theoretical promoter analysis  
 
 
HNF-beta (Foxa2)       
-435 TTTGTTTGTT TGTTTTGGTG AGGGGTGATG GAGGGAATAG GTATGGCAGC AGTATTCTTG CGGAGCAAGG 
   GR        GR 
-365 CCACCTGTCA TCTTCTTTGT GCATGCCTCC ACCCAAGCAA TCTGAGACAG TCCCCAGTCA ACAGTTGTGT 
       TREB       USF  (CREB TGACCG) 
-295 TCTCCTGCCA TTCCTAGAGT GACGTTCAAG GACACCAGTC AGACTTGAAC GCACGTGACC GCCTCGACAG 
       HES-1       RXR-alpha/RAR-beta   CREB 
-225 CTAAGGTGGC TTTCGGAGGC GGAGAGCACG AGCGGGACAG CGCCTACCGT TGTGACCCCG TGACGGGAGC  
            SP1  
-155 CCAGCGCCGG GCTGCTAACA GCTGAGCTAG AGGTCCGTCT CCGCAAGCCC CGCCCTCTGC GGCCACTCCC  
         SP1 
 -85 CGGCTTGGGC CCACCCCGAG ATCGGGGCGA GCGGCCGGGG ACTGCGAGCC ACCAAAGCTC CGCCCCGTGA 
 
 -15 GTCCTGCCCC ACCGGCAGCC CGCCGGGCCC GGTGGCCGCG GGGCCGCCTC TACGGCTAGC GGCAGTGACT   
  PPARα 
  +1 CGGCGACCTT GAACC     
 
Figure 12: Result of the theoretical promoter analysis performed with Transcription Element Search 
System (TESS), a bioinformatical tool to search for transcription factor binding sites within a determined 
region. Using another tool named PATCH a second bioinformatical promoter analysis had been 
performed. (Figure adapted from Aniko Ginta Pordes[74] )  
 
As mentioned above a first specific bioinformatical analysis had already 
been performed some years ago.[74] In order to consider new research 
results this type of theoretical analysis had to be repeated and in fact 
several new possible binding sites were proposed by TESS. For a better 
understanding the following schematic figure of the CRAT promoter shows 
the different proposed transcription factor binding sites and their relation to 
two genes, which enclose this bidirectional promotor (Crat and Ptpa).  
 
Figure 13: Schematic figure of proposed transcription factor binding sites after theoretical promoter 
analysis.  
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This re-evaluation of the CRAT promotor led to further analysis of the 
following putative binding sites, which had not been considered before:  
• USF_CREB: TESS proposed binding sites for these two different 
transcription factors in a region from 234nt to 243nt upstream the 
promoter start. According to the data generated by TESS the two 
binding sites are overlapping. Since this region is located within the 
reporter-gene assay construct mCRAT-2 apart for the last nucleotide 
(nt243) and because CREB is a multifunctional transcription factor 
this site was included for further analysis.  
• HNF3β: The binding site for the Hepatic Nuclear Factor 3 beta or 
also called FoxA2, is localized far out the mCRAT-2 construct, but 
based on the facts told by the literature that this factor is especially 
active in liver cells and it is of influence in cases of MODY (maturity 
onset diabetes of the young)[108] we decided to subject  HNF3β 
further analysis.  
• PPARα: The influence of PPARα on genes of the acylcarnitine 
transferase system has been reported repeatedly.[56],[48] PATCH 
search identified a PPARα binding site already within the first exon. 
This was reason enough for further investigation of this site.  
• Although the hitherto analysis of the other proposed transcription 
factor binding sites (SP1, RXR/RAR, GR) did not give any hints 
about the regulative mechanism of Crat transcription under L-
carnitine influence the re-analysis of these sites also had to be part 
of the thesis.  
3.2 Analysis of the proposed SP1_2 binding site 
 
SP1 an ubiquitously expressed transcription factor, can often be found in 
TATA less promoters mediating the basic transcription especially of 
housekeeping genes. Through its C(2)H(2) type zink-finger domain SP1 is 
able to activate or repress transcription of many genes. Recent evidence 
indicates that the whole SP-family has besides its “housekeeping” activity 
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also key functions as mediators of gene expression induced by insulin and 
other hormones.[109] SP1 is able to recruit the important factors 
TBP/TFIID, which allows SP1 to promote transcriptional initiation, but not 
elongation. This ability to recruit TFIID effectly explains the ability of SP1 to 
induce transcription in TATA-less promoters.[110]  
TESS search proposed two distinct binding sites for SP1 within the CRAT 
promoter. In previous band shift experiments, published by Aniko Ginta 
Pordes in her diploma thesis [74], especially the SP1 site which is closer to 
the promoter start - further on named SP1_2 - showed stronger indications 
for being involved in the regulation of CRAT transcription. Nuclear extracts 
bound the SP1_2 site with a higher efficacy than the SP1_1 site resulting in 
a stronger band shift signal.  
3.2.1 Southwestern blot 
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Figure 15: Size determination of the nuclear factor binding the 32-p labelled SP1_2 ODN through 
determination of migration length.  Signal was detected 6mm downstream the migration start resulting in 
a molecular weight of the probed protein of 105kDa. 
 
 
Figure 14: SP1 southwestern blot with 
signals proximate to the 100kDA marker.  
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The southwestern analysis showed that the binding of the γ32-ATP labeled 
ODN gave rise to a signal close to the 100kDa marker line. The subsequent 
“molwSearch” in the “Transfac database” tightened the suspicion that the 
32P-labeled oligonucleotide bound to SP1, which itself has a molecular 
weight of 105kDa.  
3.2.2 Band Shift Assays 
 
 
Figure 16: SP1 EMSA with rising L-carnitine and antibody concentrations 
 
The outcome of this mobility shift experiment approved the fact that the 
analyzed sequence is a SP1 binding site. The typical band shift pattern of 
SP1 sites can be seen above. Not only SP1 itself is binding to this element, 
also major and minor SP3 and the GC-box proteins are able to bind this 
specific element in the CRAT promoter in vitro. [111] We did not observe an 
influence of L-carnitine on the binding affinity of the nuclear abstracts to the 
32P labelled DNA probe. This supports the thesis that SP1 very likely is 
involved in the basic transcription of the CRAT gene, but is not sensitive to 
L-carnitine supplementation. 
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Figure 17: SP1 EMSA with supershift signal with extracts from dexamethasone-induced cells. 
1 
negative control 
8 
serum induction 
2 
normal 
9 
dexamethasone + 1µl SP1 antibody  
3 
0-carnitine 
10 
starvation+ 1µl SP1 antibody 
4 
40-carnitine 
11 
Serum induction + 1µl SP1 antibody 
5 
80-carnitine 
12 
40-carnitine + 1µl SP1 antibody 
6 
10 dexamethasone 
13 
80-carnitine + 1µl SP1 antibody 
7 
starvation 
 
This combined band shift and supershift experiment using the SP1-oligo 
with nuclear extracts from cells of different cultivation types showed a 
supershift in the lane 9. In this lane nuclear extracts from dexamethasone 
treated cells were loaded.   
 1   2    3    4     5    6    7    8    9   10  11  12   13 
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Figure 18: EMSA in order to determine optimal MgCl2 concentration in the reaction mix with distinct 
supershift (marked by the arrow). 
In the optimization experiments, where the ideal amount of MgCl2 should be 
determined, also supershifts were observable. The optimal MgCl2 
concentration for supershifts in this in vitro system turned out to be 2mM 
per approach. Concluding from these two band shift experiments one can 
conclude that under starving and dexamethasone supplemented conditions 
more SP1 is available or in the proper modification to bind the radiolabeled 
SP1 promotor sequence element. 
3.3 Analysis of the putative PPARα binding site 
 
Since it is widely accepted that PPARα is involved in the regulation of many 
genes of the fatty acid metabolism and also of the carnitine-acyltransferase 
system, special attention was paid to identify a possible PPARα binding 
element within the promoter or within the first exons and introns. Finally 
Patch search predicted such a putative site in the first exon just nine 
nucleotides downstream the promoter start.  
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Figure 19: EMSA with putative PPARα binding site (located in the first exon of Crat) 
 
The outcome of this band shift experiment was quite obvious. No murine 
nuclear factor was able to bind this DNA probe representing a theoretical 
PPARα binding site under the defined growth and incubation conditions.  
3.4 Analysis of the HNF-3β site 
 
Hepatocyte nuclear factor 3β is a very active transcription factor in liver 
cells and was proposed by TESS with the highest likelihood-ratio of all 
nuclear factors. Although the discussed binding site of this factor is 
localized far out of the 342nt region, which, according to previous data [74], 
it should be mainly responsible for carrying out the L-carnitine effect in 
CRAT gene expression. Therefore further analysis of this region was 
mandatory. HNF-3β was described to be a transcription factor, which 
promotes the transcription of genes that are involved in glucose 
homeostasis.[112] Since CRAT can be seen as a modulator between beta-
oxidation and glucose utilization, due to its impact on the 
pyruvatedehydrogenase complex, a possible regulative influence of HNF-
3β on CRAT transcription seemed quite comprehensible.  
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Figure 20: HNF-3β mobility shift assay 
 
Apparently this distinct HNF-3β site is a target for nuclear factors. Mobility 
shift experiments with this sequence box resulted in a double-shift pattern, 
displaying that two different factors with different molecular weight are 
binding this site. Under starvation the band shift signal turned out to be 
weaker indicating decreased binding of nuclear proteins to the 
oligonucleotide. After treatment of the cells with dialyzed fetal calf serum, 
the binding of nuclear factors to this ODN was increased in comparisons to 
the “normal-status” (nuclear extracts from cells cultivated in 
DMEM+10%FCS+Ab). An influence of L-carnitine could not be observed as 
indicated in lanes 7-10.  
1 Negative control 7 DMEM + dialysed 10%FCS+ 40µM L-Carn.  – 4h 
2 DMEM+10%FCS (N) 8 DMEM + dialysed 10%FCS+ 80µM L-Carn. – 4h 
3 Starvation 9 DMEM + dialysed 10%FCS+ 120µM L-Carn. - 4h 
4 Serum Induced 10 DMEM + dialysed 10%FCS + 80µM L-Carn. 24 h 
5 N+10µM Dexamethasone 11 N+10µM Dexamethasone 24 hours 
6 DMEM + dia. 10%FCS(0-C)  12 N+5µM Dexamethasone 
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Considering these results and the fact that the HNF-3β binding site is 
located far out of the 342nt-carnitine sensitive region we can exclude this 
regulative element from being included in the L-carnitine induced 
upregulation of the CRAT gene expression.  
About possible regulative effects of HNF-3β on the gene regulation of PTPA 
further experiments would be interesting, but from the point of knowledge 
we have now, no serious prediction can be made whether this factor is a 
regulative element of the Crat or the Ptpa gene.  
3.5 Analysis of the GR site  
 
The glucocorticoid receptor (GR) is a member of the nuclear receptor 
superfamily, composing subfamily 3C.[113] The unbound receptor is 
located in the cytoplasm and moves after binding its substrate into the 
nucleus where it recognizes its consensus sequences. From this point on, 
the glucocorticoid receptor closely linked to its activating steroid has two 
major tasks. On the one hand it promotes the expression of anti-
inflammatory genes and on the other hand it works as a repressor for pro-
inflammatory genes.[114]  
In this case again the connection of the GR elements to the energy 
metabolism – glucocorticoids elevate the blood sugar – was reason enough 
for a repetition of the analysis of this specific promoter element. A 
connection between L-carnitine and glucocorticoid receptors had already 
been reported. In vitro administration of pharmacological dosage of L-
carnitine can activate GRα and subsequently modulate the transcription of 
glucocorticoid-responsive genes. This provides a way to explain the 
immunosuppressive properties of L-carnitine by mimicking glucocorticoid 
actions.[115] 
 56 
 
Figure 21: EMSA with the GR element from the Crat promoter 
 
This mobility shift assay revealed an interesting phenomenon and also 
posed further questions. First of all one can see that under physiological 
conditions (DMEM+10%FCS+Ab), starvation and serum induction obviously 
2 different factors or factor complexes can bind the GR-element 
representing oligonucleotide. But in those experimental approaches where 
the pathophysiological status of hyperlipidemia and hyperglycemia were 
simulated the upper band shift signal diminished. The homeostatic changes 
supported the disaggregation of the DNA-protein complex.  
A GR mobility shift assay resulting in a double band shift, like the one 
illustrated above, seems to be a common pattern for glucocorticoid 
responsive elements. Gao et al. performed also EMSAs with a GR element, 
which produced a double band pattern. [116]  
 
3.6 Analysis of the USF_CREB Site 
 
TESS search also proposed a special site within the CRAT promoter where 
according to the program two overlapping binding sites for different factors 
are located. On the one side TESS propounded a USF-1 element. 
Upstream stimulating factor 1 is also an ubiquitously expressed 
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transcription factor, which has been linked with the etiology of familial 
combined hyperlipidemia and metabolic syndrome.[117] 
On the other side also a possible binding site for the well-known 
transcription factor CREB has also been located within this specific area.  
CREB is the final target of many signaling pathways and its effects are 
manifold. It plays an important role in neuronal plasticity and memory, 
neuronal development and is also involved in addictional behavior.[118] 
Above that it is involved in many metabolic processes like fat metabolism 
and hepatic gluconeogenesis. Its regulative role in the response to nutrient 
and hormonal changes has also been described. [119],[120] In addition  
muscle cell energy homeostasis is regulated by CREB. 
Via the AMP-activated protein kinase (AMPK) CREB gets phosphorylated 
and controls together with coactivators like PGC-1α the capacity of fatty 
acid oxidation.[121]  
This pathway including CREB and PGC-1α is also involved in CPT1a 
transcriptional regulation, especially after starvation CPT1a expression is 
upregulated in response to glucagon release from the pancreas, a process 
that is mediated by cAMP.[31]  
Analysis of the proposed DNA region revealed that the putative USF-1 
binding site is located at the very beginning of the reportergene assay 
construct mCRAT-2 except for the nucleotide 243 upstream the promotor 
start which is just outside this construct. This sequence has been split 
during the generation of the constructs for the reportergene analysis. An 
important fact that has to be considered is that one has to be able to 
analyze the results of these experiments correctly. 
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             1      2      3     4     5      6       7     8      9    10   11    12    13 
 
Figure 22: Mobility shift assay with the USF1-Creb 32-P-labelled ODN 
 
1 
negative control 
8 
serum induction 
2 
normal 
9 
5 dexamethasone 
3 
0-carnitine 
10 
10 dexamethasone 
4 
40-carnitine 
11 
starvation + 1µl Creb antibody 
5 
80-carnitine 
12 
80-carnitine + 1µl Creb antibody 
6 
120-carnitine 
13 
10-dexamethasone + 1µl Creb antibody 
7 
starvation 
 
The outcome of this experiment is quite meaningful. First of all it generates 
a typical single band shift signal that only one factor or factor complex is 
able to bind this specific DNA probe. A general look at the fluorographic 
radiofilm reveals that starving conditions led to strong binding of nuclear 
factors to the ODN probe. It is also evident that rising L-carnitine levels led 
to weakening of the signal. Another interesting result was that a weak 
supershift signal is visible in lane 11, where the nuclear extract of starved 
cells in combination with a CREB antibody was analyzed. So very likely this 
sequence element of the Crat promoter harbors a CREB binding site to 
which especially under starvation nuclear factors showed high affinity.   
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3.7 Analysis of the RXRα/RARβ binding site 
 
From the very beginning of the investigation of the Crat promoter this 
element had been the most interesting and most promising one. Already my 
colleague Ginta Pordes published that this element showed the strongest 
band shift signals after L-carnitine induction[74]. But so far no supershifts or 
other more defining results could be achieved. Nevertheless this element 
stayed in the center of research for several reasons:  
• This RXRα element is highly conserved and also present in the 
human CRAT promoter.[74] 
• The retinoic x receptor α is able to form heterodimers with many 
other nuclear receptors which are involved in fatty acid metabolism 
like PPARα and LXRα.[122] 
• Its role in insulin resistance has been described. This aspect 
appeared to be interesting since the accumulation of metabolites of a 
defective fatty acid degradation was also linked to insulin 
resistance.[123]  
 
3.7.1 Band Shift and Supershift Assays 
 
In the first experimental approaches with the RXRα/RARβ probe the focus 
had been set on possible factors interacting with this special region based 
on the results of the TESS search. From this starting point supershift 
assays with possible interacting factors of RXRα, which were defined as 
such by Pubmed, were performed.  
3.7.1.1 RORα Supershift Assay 
 
The first candidate in this screening was the RAR-related orphan receptor 
alpha (RORα), a member of the steroid hormone receptor superfamily. 
Studies with ROR deficient mice showed the importance of this receptor for 
several physiological processes. For instance its central role in 
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development of the cerebellum was described. It was also implicated that 
ROR is a key regulator in the maintenance of bone tissue and RORα 
deficient mice were more susceptible to arteriosclerosis.[124] Above that 
cholesterol and 7-dehydrocholesterol were identified as RORα ligands, 
which led to the awareness that this nuclear receptor is interfering with the 
regulation of lipid homeostasis.[125] These reasons made this factor also 
interesting for closer investigation in correlation with the Crat gene.  
 
Figure 23: RXRα/RARβ EMSA with anti-RORα antibodies for supershift analysis 
 
This experiment with the RXRα/RARβ ODN probe resulted in two distinct 
band shifts at different migration distances. A supershift as described for 
the SP1 and the CREB site could not be observed. The outcome from this 
approach is that this nuclear factor RORα can be excluded from binding to 
this promoter element.  
3.7.1.2 PPARγ Supershift Assay 
 
Another heterodimerization partner of RXR is the Peroxisome proliferator 
activated receptor gamma (PPARγ). This heterodimer binds a specific DNA 
sequence called PPAR Responsive Element (PPRE). [126] 
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After docking to this PPRE the binding of endogenous and exogenous 
factors like fatty acids and eicosonoids takes place leading to cofactor 
recruitment and subsequent transcriptional regulation.[127]  
The PPARγ receptor plays a very important role in fat cell differentiation by 
inducing fatty-acid metabolism specific genes and promoting the formation 
of lipid-rich adipocytes.[128] Experiments with PPARγ deficient mice 
revealed the importance of this factor for the development of white and also 
brown adipocytes.[129]  
This critical involvement suggested a possible regulative role in the 
transcriptional control mechanisms of Crat expression.  
 
 
Figure 24: RXRα/RARβ EMSA with anti-PPARγ antibodies for supershift analysis 
 
The outcome of this experiment is quite similar to the one of the RORα 
supershift assay. The EMSA resulted in a double-banded shift but no 
supershift signal indicating that PPARγ is not binding to this specific 
RXRα/RARβ probe from the Crat promoter. 
3.7.1.3 PPARbP(TRAP220) Supershift Assay 
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The next factor, which had been tested in these first screening experiments, 
was the PPAR binding protein (Pbp), or also called TRAP220 or MED1. It is 
a multiprotein coactivator that is needed by DNA-binding transcription 
factors in order to activate the RNA-Polymerase II.[130]  
Pbp is also able to interact with PPARγ, PPARα, RARα, RXRα, and TR-β in 
vitro. All mentioned factors are involved in the fatty acid metabolism. It has 
been proposed that Pbp is an important coactivator for the physiological 
functions of PPARs in energy homeostasis.[131]  
Another important certainty, which made PPARbp very interesting in 
correlation with the Crat promoter, was the fact that the PPARbp gene itself 
gets upregulated by L-carnitine after artificial L-carnitine deficiency. Elke 
Hofer-Litzlbauer showed in her doctoral thesis with RNA-microarrays and 
reverse transcriptase RT-PCR that the mRNA levels of cells induced with 
80 µM L-carnitine exhibited 12-fold higher levels in comparison to L-
carnitine lacking cells.[132]  
 
Figure 25: RXRα/RARβ EMSA with anti-TRAP220 antibodies for supershift analysis 
 
The anti-TRAP220 antibody had quite an impact on the shifting features of 
the nuclear extracts in combination with the γ32-phosphate labeled 
oligonucleotide. Rising antibody concentrations (from 0-4ng of a 200µg/ml 
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concentrated antibody stock solution) provoked a weakening of the lower 
band shift signal at 0µM L-carnitine (cells cultivated with dialyzed FCS) and 
nearly a disappearance of the lower signal at 40µM L-carnitine (cells 
cultivated with dialyzed FCS and supplemented with 40 µM L-carnitine for 
four hours).  
3.7.1.4 Extended RXRα/RARβ Band Shift Assay  
 
For better understanding of the band-shift patterns previous EMSAs 
presented, further experiments had to be performed with the aim to 
generate better resolution on the X-ray films. Because of this reason the gel 
electrophoretic conditions had to be changed and running time was 
extended for two hours.  
 
 
Figure 26: EMSA with RXRα/RARβ dsODN probe after elongated gel electrophoresis 
  
As one can observe on the X-ray film depicted above, mobility shift assays 
with the RXRα/RARβ probe resulted in shifts with three distinct bands. 
Elongated gel electrophoresis showed that the lower shifting signal, which 
diminished in the TRAP220 supershift assay, was in reality the joint product 
of two distinct band shifts. Obviously the difference in molecular weight of 
these two factors causing this double band is quite small.   
1 neg. control 
2 dialyzed FCS 
3 dialyzed FCS + 40µM L-carnitine 
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3.8 Evaluation and conclusion of the first screening 
experiments 
 
Since these experiments resulted in band shifts with three distinct bands, 
but no supershift could be observed, the used oligonucleotide representing 
the promoter-site of interest had to be re-evaluated and examined with 
another bioinformatical tool. The analysis with the search tool Patch[106] 
revealed that a hitherto not known transcription-factor binding site was 
included in this oligonucleotide, namely a c-AMP responsive element 
(CREB). 
 
CCTACCGT TGTGACCCCG TGACGGG 
Figure 27: The sequence marked in red represents our “old” RXRα/RARβ element. The green one marks 
the sequence that Patch identified as a CREB binding site. 
 
Another result of the Patch search was that it proposed further interaction-
partners for the RXRα/RARβ locus.  
 
Factor Sequence direction 
   PPAR-alpha 
   RXR-alpha 
TGAACC Sense 
   VDR TGACC Sense 
   RAR-alpha1 
   RAR-beta2 
   RAR-gamma1 
GTTCA antisense 
   RAR-beta 
   RXR-alpha 
   RXR-beta 
GGTTCA antisense 
   RXR-alpha 
   VDR 
GGTTCA antisense 
 Table 1:Putative interacting transcription factors for the RXRα/RARβ locus.  
 
Due to these results the “old” RXRα/RARβ ODN probe had to be split and 
the following oligonucleotides were synthesized in order to analyze the two 
different binding sites separately.  
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5’ AGCGCCTACCGTTGTGACCCCG 3’  RXR_2 Sense 
 
5’ CGTGACGGGAGCCCAGCGCCGG 3’ CREB_1 sense 
Figure 28: Oligonucleotides RXR_2s and CREB_1s 
 
3.8.1 Southwestern Blot 
 
The main “suspect” remained the RXR site since this factor is able to 
correspond with many different putative interaction partners. A special 
experimental approach, the so called ”Southwestern Blot” analysis, allowed 
to determine the molecular weight of the factors binding this specific 
oligonucleotide, which again had been labeled with radioactive 32P-ATP.  
 
Figure 29: Southwestern Blot shows the binding of the radioactive-labelled RXR_2 probe to specific 
proteins 
 
For southwestern analysis of the RXRα element nuclear extracts from cells 
of 3 different cultivation conditions (normal, dialyzed FCS, dialyzed 
FCS+80µM L-carnitine) were analyzed. The radiographic analysis of the 
blot revealed three distinct bands in each lane.  
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Figure 30: Size determination of the proteins on behalf of migration length of the proteins after 
denaturing SDS-Page 
 
To determine the molecular weight of these three proteins a standard curve 
was calculated by using the migration length of the molecular weight 
markers. (Fermentas PageRuler Unstained Protein ladder). After 
determination of the migration distance of the unknown proteins their size 
could be determined: 
 
Band 1 145kDa 
Band 2 70 kDa 
Band 3 51 kDa 
 Table 2: Molecular weight of the RXR_2 probe binding proteins 
 
The subsequent “molwSearch” using the “Transfac Database” from the 
website www.gene-regulation.com presented LXRα and PPARα as 
candidate factors within a size range from 51-53kDa for the lowest protein 
signal, c-MYB and c-MYC as putative factors for the ∼70kDa band and EVI-
1 for the ∼145kDa band signal. 
These proposed factors and their possible metabolic functions had been 
further on examined by using the OMIM database and Pubmed:  
• Peroxisome proliferator-activated receptor α (PPARα) and liver 
x receptor α and β (LXRα/β) are reciprocal regulators of the fatty 
acid metabolism.[133] More importantly their central role in the 
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regulation of other genes of the carnitine acyltransferase system 
made those two factors highly interesting for also being involved in 
the carnitine induced gene expression of Crat and the rest of the 
connected “carnitine-shuttle” system (Cpt1a, Cact, Cpt2).[22],[56], 
[48]  
• Activation of the proto-oncogene EVI-1 (Ecotropic viral integration 
site 1) gene expression has been described for being related to 
murine myeloid leukaemia.[134] This factor is also able to induce a 
myelodysplatic syndrome in mice. [135] 
• c-Myc is a transcription factor which has been identified as a proto-
oncogene, which can activate and repress transcription in 
combination with c-Max as a heterodimer. Due to its central role in 
cell functions during mitosis and cell growth deregulation of c-Myc 
can lead to genetic alterations, whereas constitutive activity of c-Myc 
is involved in the genesis of a manifold variety of cancers.[136] 
Especially the Burkitt’s lymphoma, a Non-Hodgkin lymphoma, had 
been connected with hyperactivity of c-Myc. [137]  
The influence of c-Myc on the liver metabolism was described in so 
far, that hyperactive c-Myc down-regulates PPARα controlled genes 
belonging to the fatty acid catabolism. On the other side it raises the 
transcriptional rate of genes controlled by SREBP-1 that promote the 
anabolism of fatty acids and cholesterol.  [138, 139] 
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3.9 Analyses of the oligonucletides RXR_2 and CREB_1  
 
 
Figure 31: comparative EMSA of the three dsODN probes RXR_1, RXR_2 and CREB_1 
 
This experiment confirmed the thesis that the RXR_1 probe (the “old” 
RXRα/RARβ element) really contained binding sites for two different 
transcription factors or factor complexes.  
As the figure illustrates, the nuclear extracts with the probes RXR_2 and 
CREB_1 showed band shift signals at the same height, whereas the shift 
experiments with the RXR_1(RXRα/RARβ) oligonucleotide probe resulted 
in two distinct signals. The upper band shift represents some kind of a 
“supershift” as a result of the binding of two different factors to the RXR_1 
oligonucleotide, each binding to its specific DNA motif leading to more 
bound protein and further on to shorter migration during gel-
electrophoresis.  
3.9.1.1  PPARα supershift assay with the RXR_2 ODN 
 
The first supershift assay with the newly synthesized RXR_2 element was 
performed with extracts of normal treated, dialyzed and L-carnitine 
supplemented cells and anti-PPARα antibodies.  
  69 
 
Figure 32: RXR_2 EMSA and anti-PPARα antibodies for supershift analysis 
 
 
Increasing antibody concentration led to a weakening of the band shift 
signal under carnitine deficient conditions and especially after 
supplementation with 80 µM L-carnitine. The antibody reduced or 
hampered the formation of the protein-DNA complex indicating that PPARα 
is part of this complex. A classical supershift band was not visible, but 
according to the literature, reduction of the signal after application of the 
antibody is equivalent to a supershift signal. Obviously the antibody blocked 
the DNA binding domains of the PPARα protein. [140] 
 
 
Figure 33: PPARα supershift analysis with RXR_2 probe resulting in a reduced formation of the DNA-
protein complex 
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A very good insight into the binding features of nuclear extracts to the 
RXR_2 ODN gave the supershift approach depicted above. Obviously, as 
expected from previously generated data by our lab, increasing L-carnitine 
concentrations in the growth-media during cultivation of the TIB73 cells led 
to stronger affinity of the proteins to the examined promoter element. The 
double band shift pattern got stronger with increasing L-carnitine 
concentrations. Application of anti-PPARα antibody solution resulted in the 
characteristic reduction of the band shift signal. At 40 µM L-carnitine only 
the upper signal diminished but at highest L-carnitine and antibody 
concentrations the whole signal got nearly extinguished.  
3.9.1.2 LXRα/β supershift assay 
 
LXRα/β, antagonistic factors to PPARα in the regulation of energy 
metabolism genes, are also able to build heterodimers with RXRα. Thus the 
possible involvement in the regulation and mediation of the “L-carnitine” 
effect should also be explored with band and supershift assays.  
 
Figure 34: combined LXRα-PPARα supershift analysis with RXR_2 probe resulting in a reduced formation 
of the DNA-protein complex 
 
The administration of the LXRα/β antibody seemed to have a similar effect 
on the binding affinity of the nuclear extracts to the 32P labelled dsODN. 
With increasing L-carnitine concentration and constant anti-LXRα/β 
antibody the band shift signal got weaker again and almost disappeared. 
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First at 40 µM L-carnitine again the upper signal diminished first and 
secondly at 80µM L-carnitine also the lower band shift signal got weaker. In 
presence of both antibodies, namely anti-PPARα and LXRα/β, the effect 
remained the same and the shift signal disappeared almost completely. 
3.10  PPARα Western Blot 
 
In a Western Blot analysis the effect on PPARα expression itself under         
L-carnitine influence had to be examined. Again nuclear extracts from 
differently treated cells were used in order to see if time dependent 
administration of L-carnitine would lead to upregulation of PPARα protein in 
the nucleus.  
 
Figure 35: PPARα Western Blot illustrating the increase of PPARα with time after L-carnitine 
administration 
This blot provided more indications that the PPARs, especially PPARα, and 
L-carnitine metabolism are directly connected and influence each other. 
Clearly visible is a time-dependent PPARα expression, after 24 hours after 
administration of 80 µM L-carnitine increased protein synthesis did take 
place that could explain the stronger blotting signals at the time points 15h 
and 24h.  
3.11  Real-Time RT PCR 
 
In previous projects the influence of L-carnitine on the transcription rate of 
genes involved in the L-carnitine metabolism had been shown in different 
human cell lines by RT-real time PCR[141]. Aniko Ginta Pordes showed in 
her diploma thesis by luciferase reporter gene assays the effect of L-
carnitine on CRAT gene expression in the murine liver cell lines TIB73 and 
NIH3T3.[74] Therefore one task for this thesis was to support this “L-
carnitine effect” in murine cells by real-time RT-PCR analysis. For this aim 
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Crat transcription levels had to be tested under the influence of L-carnitine. 
In order to compare these expression levels also with other genes of the 
carnitine acyltransferase family (Cpt1a, Cpt2, Cact, Octn2) had to be 
analysed.  
Further on also the Crat gene expression under different metabolic 
conditions like as hyperlipidemia, hyperglycemia, and starvation were of 
interest. These aspects also supported the research goal to search for 
other inductors and inhibitors of Crat gene expression.  
3.11.1 Real Time analysis of Carnitine Acetyltransferase 
 (Crat)  gene expression  
3.11.1.1 Concentration dependent influence of L-Carnitine on Crat 
 gene expression 
 
 
Figure 36: Real Time Analysis after administration of rising L-carnitine concentrations (0-120µM) for 4 
hours (n=4) 
 
As expected due to knowledge from previous experiments Crat mRNA 
levels increased with higher L-carnitine levels. Already at a supplemented 
concentration of 40 µM L-carnitine a tendency for induced Crat transcription 
is observable, although the value of 1.12 (p>0.05) did not reach statistical 
significance in a students-t test.  
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Cells induced with 80µM L-carnitine already showed significant higher Crat 
mRNA levels in comparison to those cells grown under L-carnitine 
deficiency. A 1.27-fold increase could be reached (p<0.05).  
1.46-fold was the increase of Crat mRNA expression in TIB73 cells under 
supplementation with already unphysiologically high 120µM L-carnitine 
(p<0.001).  
3.11.1.2 Time dependent CRAT gene expression after 
 supplementation of 80 µM L-carnitine  
 
 
Figure 37: Time dependent transcript levels of the murine Crat gene after initial administration of 80µM L-
carnitine (n=4) 
 
The analysis of Crat transcription in dependence of time shows for the first 
twelve hours a typical Gauß-shaped curve of transcript induction. After 4 
hours the highest mRNA levels of the Crat transcript were reached. 
Afterwards the Crat mRNA steady state level decreases, either due to the 
lack of transcription or constant degradation, reaching a minimum after 12 
hours. After 15 hours of incubation re-administration of new 80 µM L-
carnitine had been performed and a peak occurred again after 18 hours of 
initial carnitine supplementation.  
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Figure 38: Results of Real Time PCR after second administration of 80 µM L-carnitine 15 hours after the 
initial one (n=4) 
The re-administration of L-carnitine 15 hours after the initial dosis resulted 
in even higher mRNA levels (2.23 fold, p<0.001) after 3 hours of reinduction 
(or 18 hours of total induction). 6 hours later (24 hours after first L-carnitine 
administration and 8h after reinduction) still an increased Crat mRNA level 
of 1.41 (p<0,001) was measured.  
3.11.2 Pharmacological aspects of CRAT gene expression 
 
The regulative effect of PPARα on genes of the carnitine acyltransferase 
family was reported several times [142]. Since the data from the band shift 
assays described before also delivered strong indications that PPARα and 
LXRα are regulative factors for the transcription of Crat, agonists for the two 
transcription factors became part of our investigations. Fibrates like 
fenofibrate and clofibrate offered themselves as candidates for PPARα 
agonists.  
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3.11.2.1 Influence of fenofibrate on Crat mRNA levels 
 
 
Figure 39: Impact of fenofibrate on Crat mRNA transcription levels (n=4) 
 
Quite impressive was the induction of the Crat transcription after 
administration of the PPARα agonist fenofibrate. Cells treated with this 
hyperlipidemic drug showed already at 10µM a 5-fold increase in Crat 
mRNA after 3 hours of treatment in comparison to non-treated cells 
(p<0.001). The administration of 40µM fenofibrate even resulted in a 11-fold 
higher mRNA level (p<0.001).  
3.11.2.2 Influence of Clofibrate on Crat mRNA levels 
 
 
Figure 40: Effects of clofibrate on Crat gene expression (n=3) 
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The treatment of cells with clofibrate and the following analysis of the 
mRNA levels showed a completely different outcome than described above. 
Increasing clofibrate levels led to reduction of Crat transcription resulting in 
a decrease of the mRNA level 0.25-fold at a concentration of 40 µM 
clofibrate.  
An important observation to mention in connection with these experimental 
data is the induction of apoptotic processes in cell culture cells checked 
under the microscope during the treatment. TIB73 showed also kind of fat 
mobilization and vacuolization during clofibrate treatment. Shortly after 
administration of this hyperlipidemic drug drops of lipid aggregates or 
grease were observable in the media. 
3.11.2.3 Influence of the LXR-agonist GW3965 on Crat mRNA 
 levels 
 
 
Figure 41: Impact of the LXRα agonist GW3965 on Crat transcription levels (n=3) 
 
Cells treated with GW3965, a LXRα agonist, showed at lowest levels 
(0.5µM and 1µM) non-significant indications of increased Crat mRNA levels 
(p>0.05), but at the highest GW3965 level used (1,5 µM) an inhibitory effect 
(decrease to 0.8 in comparison with untreated cells) was observable 
(p<0.05).  
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3.11.2.4 Influence of Retinoic Acid on Crat mRNA levels 
 
Retinoic acid is a substrate for the RAR nuclear receptor. Since theoretical 
promoter analysis proposed at first a RXRα/RARβ element, a possible 
influence of this compound on Crat expression had to be examined.  
 
 
Figure 42: Retinoic acid and its influence on Crat mRNA levels 
 
Already the administration of small amounts of retinoic acid, in this case 
5µM, caused a significant decrease of Crat mRNA levels and reached only 
half the amount than the control did (0.53, p<0.001). This level kept quite 
constant with increasing concentrations from 10 µM (0.69, p<0.01) to 15 µM 
retinoic acid (0,56, p<0.001).  
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3.11.2.5 Metabolic influences on Crat gene expression 
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Figure 43: Crat mRNA levels under different metabolic influences 
 
Analysis of the mRNA levels of the simulated metabolic conditions 
“starvation” and “serum induction” revealed increased transcription levels of 
Crat under starvation conditions (up to 2-fold induction). In serum induced 
murine liver cells Crat transcription got downregulated to a level of 0.48 fold 
in comparison to normally grown cells (DMEM+10%FCS).  
 
3.11.3 Comparison of transcription levels between the 
different carnitine acyltransferase genes during L-carnitine 
deficiency and supplementation 
 
The transcript levels of human carnitine acyltransferases are L-carnitine 
dependent. Under L-carnitine deficiency the mRNA levels of the three 
transferases CRAT, CPT1a and CPT2 were 2-3 fold down regulated in 
human cell systems in vitro.   
L-carnitine supplementation can restore original transcript levels or even 
raise them.[141] These findings had to be tested and confirmed in the 
murine liver cell line TIB73 as well.  
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A time dependent analysis of mCrat levels is shown above. In order to get 
an understanding whether other members of the carnitine-shuttle system 
react similarly, transcription levels of the murine homologues to the genes 
described above had to be determined. In addition to the carnitine 
acyltransferases we included the transport proteins Cact and Octn2 in this 
analysis.  
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Figure 44: time course of mRNA levels of genes of the “carnitine-shuttle-system” after initial 
administration of 80µM L-carnitine and re-induction after 15h. (n=5) 
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Figure 45: 3-D figure of mRNA levels of “carnitine-shuttle” genes after 80µM L-carnitine supplementation 
(n=5) 
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The mRNA levels of the 5 compared genes respond quite similar to L-
carnitine administration with only slight differences. After one initial 
application of 80µM L-carnitine Octn2 and Crat reached their highest levels 
of mRNA expression after 4 hours, whereas Cpt2 reacted faster and had its 
highest transcript level already after 2 hours of L-carnitine supplementation. 
Cpt1a and Cact mRNA induction reached their highest levels after 6 hours. 
Afterwards a constant decrease of the mRNA steady state levels reached 
its initial amount after 12 hours.  
Octn2 showed the strongest response to L-carnitine by raising its transcript 
level 2.6 fold (p<0.001) after 4 hours. Also the induction of the other four 
genes was statistically significant (Crat as described above; Cact: 1.4 fold 
after 6 hours, p<0.001; Cpt1a: 2.38 fold increase after 6h, p<0.001; Cpt2: 
1.8 fold increase after 2 hours, p<0.001). 
Very impressive was the transcriptional behavior of these genes after a 
second administration of 80µM L-carnitine 15 hours after the first one. 
Again Octn2 responded the strongest with a 6.3 fold higher mRNA level in 
comparison with the untreated cells (p<0.001). The transcript level 
increased not that fast as they already did after the first administration of L-
carnitine. 9 hours after the second L-carnitine “shot” and 24 hours after the 
first one, Octn2 mRNA level reached its absolute highest peak mRNA level 
at all.  
Also the transcripts of Cpt1a, Cpt2 and Cact reach their highest levels 9 
hours after re-induction. (Cpt1a: 4.4 fold increase, p<0.001; Cpt2: 3.4 fold 
increase, p<0.001, Cact: 4.6 fold increase p<0.001). 
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mRNA levels of carnitine acyltransferases after induction with 
different amounts of L-carnitine
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Figure 46: comparative expression levels of Crat mRNA after administration of different concentrations of 
L-carnitine for 4 hours.  
 
As described above Crat expression reached its highest level with 
supplementation of 120µM L-carnitine. As Figure 46 clearly illustrates that 
the genes of the four other members of the carnitine-shuttle system showed 
their biggest response after the administration of 80µM L-carnitine. Higher 
levels of L-carnitine in the media seem to have already inhibitory effects on 
transcription in this case.  
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3.12 Pharmacological effects of fenofibrate, GW3965 and 
retinoic acid on transcription levels of Cpt1a, Cact, 
Octn2 and Cpt2 
3.12.1 Influence of fenofibrate on transcription-levels of 
“carnitine shuttle” genes 
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Figure 47: mRNA levels of “carnitine-shuttle genes” after administration of the PPARα-agonist fenofibrate 
 
As the knowledge from the literature predicted, all members of the murine 
carnitine-shuttle system are inducible by PPARα agonists, in this case by 
the anti-hyperlipidemic drug fenofibrate (20µM). For all the members 
depicted above the PPARα sensitive PPRE have been defined and 
mapped, except for CRAT.  
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3.12.2 Influence of GW-3965 on transcription-levels of 
“carnitine shuttle” genes 
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Figure 48: mRNA levels of “carnitine-shuttle genes” after administration of the LXR-agonist GW3965 
 
Liver X Receptors α and β have been described as reciprocal factors to 
PPARα. For this reason the impact of the LXR agonist GW3965 on the 
murine carnitine-shuttle system was tested by RT-PCR. As the figure above 
indicates, GW3965 has no significant impact on the transcription levels of 
the discussed genes.  
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3.12.3 Influence of the retinoic acid on transcription-levels 
of “carnitine shuttle” genes 
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Figure 49: mRNA levels of “carnitine-shuttle genes” after retinoic-acid supplementation 
 
As already mentioned in the introduction it was shown that 9-cis retinoic 
acid is able to induce transcription of CACT [53]. Since PPARα forms 
heterodimers with the Retinoid X Receptorα (RXRα) possible influences of 
retinoic acid on transcriptional regulation of the genes of the carnitine 
shuttle system. Whereas retinoic acid has an inhibitory effect on murine 
Crat, it enhances Cact transcription (2-fold induction). The other members 
of the carnitine-shuttle system Cpt2, Octn2 and Cpt1a were not significantly 
influenced by retinoic acid.  
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4 Discussion 
 
One major goal of this project was the characterization of the Crat 
promoter. As it could be shown in this thesis mobility shift assays are 
powerful tools to examine the binding of nuclear factors to specific promoter 
elements. Especially in combination with southwestern blotting, possible 
candidate factors can be curtailed more precisely due to the fact that the 
molecular weight can be defined.  
With this combined tools it was possible to show that the Crat promoter 
harbours a functional Sp1 binding site. As the analysis of this specific 
promoter element with supershift assay showed, it is very likely that this site 
enables basic transcription of Crat. Especially under starvation conditions 
and after dexamethasone induction this Sp1 site seemed to be very active.  
Another element, namely a CREB binding site, which is located about 210nt 
upstream this Sp1 site showed also response to starvation conditions. 
Supershift signals indicated the binding of CREB to this sequence after 24 
hours of starvation. The results of the RT-PCR analysis that showed a 1.9 
fold increase of Crat expression under starving conditions support the 
above-described findings.  
The main aim of this thesis was the identification of the factor/s mediating 
the previously described “carnitine effect”.[74, 132, 141] Many experiments, 
all conducted in our laboratory, showed the increase of transcription levels 
of many different genes after administration of L-carnitine after artificially 
induced carnitine deficiency. With this work we could provide evidence that 
the nuclear receptors PPARα, LXRα/β and PPARbP are involved in the 
upregulation of Crat gene expression after carnitine administration. The 
analysis of a specific sequence in the Crat promoter, which had been 
defined by bioinformatical analysis as a RXR/RAR binding site, led to these 
findings. Southwestern blot analysis revealed the size of protein factors 
binding to this promotor element and herewith named possible candidates. 
These candidates were closer examined via supershift assays. These band 
shift experiments resulted in an interesting and unexpected weakening of 
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band shift signals with rising carnitine concentration in presence of 
antibodies against PPARα, LXRα/β and PPARbP. Supershift assays with 
other candidate factors like RORα, Nurr77 or RARγ did not cause any 
significant change of the band shift pattern.  
Cross-talk between these factors had been described several times.[133, 
143, 144] Especially LXRα and PPARα form an important signalling axis 
controlling metabolic and energy homeostatic pathways.[145]  
Both factors, PPARα and LXRα form heterodimers with RXR. PPARα/RXR 
heterodimers bind to PPREs and enhance the expression of genes 
responsible for fatty acid oxidation and transport. [146] LXRα/RXR 
heterodimers bind to LXREs. LXRα and LXRβ are both dominant activators 
of SREBP-1c, which regulates lipid homeostasis.[147] LXRs are important 
for expression of fatty acid synthesis genes.[148]  
PPARα and LXRα/SREBP-1c are reciprocal regulators of fatty acid 
metabolism. PPARα inhibits the formation of LXRα/RXR heterodimers and 
vice versa. Also the direct interaction between LXRα and PPARα was 
shown via two-hybrid system. [133] So if metabolism requires fatty acid 
oxidation PPARα enhanced oxidation of fatty acids and simultaneously 
inhibits LXR signalling and subsequently fatty acid synthesis and storage. If 
the opposite metabolic pathway is needed LXRα becomes the dominant 
factor and inhibits PPARα signalling leading to fatty acids synthesis and 
storage. [143] A theoretical mechanism and interaction of L-carnitine is 
depicted below in Figure 50.  
Our band shift experiments implicate the interference of L-carnitine with this 
RXR/PPARα/LXRα signalling axis.  
The importance of PPARα in Crat gene expression was supported by RT-
PCR data. Administration of fenofibrate, a PPARα agonist led to 11-fold 
upregulation of Crat transcription (Figure 39). But no influence of LXR on 
Crat transcription was observable after the administration of GW3965, a 
LXRα agonist (Figure 41).  
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Figure 50: Model of the PPAR/LXR signalling axis and the possible influence of L-carnitine (adapted from 
Ide et al, 2004) 
 
The direct interaction of PPARα with the discussed promoter sequence had 
been indicated through the PPARα supershift assay as depicted in Figure 
33. Although there is no distinct supershift signal visible, this kind of 
“supershift” namely the weakening of the band shift signal was described 
and interpreted as a proof for interaction of certain proteins with the labelled 
ODN of interest. [140]  
The examined sequence can be seen as an imperfect PPRE (PPAR 
responsive element). The accepted PPRE consensus sequence was shown 
to be a direct repeat of TGACCG separated by 1 nucleotide (DR1) flanked 
by an A/T rich sequence. [149] Based on the results we propose an 
imperfect PPRE with one mismatch in each consensus sequence and two 
nucleotides separating these repeats: TGACCCCGTGACGG. Binding of 
PPARα/RXRα heterodimers to such imperfect PPREs and functionality was 
shown before for instance in the CPT2 and OCTN2 promoters. [56, 63]  
The third factor, which showed indications of being of influence to Crat 
expression after L-carnitine supplementation had been PPARbP or Trap220 
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(Figure 25). Interestingly again a weakening of the band shift signal could 
be observed with rising L-carnitine concentration in the cultivation medium 
and antibody concentration in the band shift approach. This outcome very 
nicely fits to the results from a microarray analysis a different approach, 
where PPARbP (PPAR binding protein) itself got upregulated by L-
carnitine. The administration of 80µM L-carnitine after artificially induced 
carnitine deficiency led to 12.04-fold increase of PPARbP mRNA levels.  
PPARbP was needed as a cofactor by PPARα for transcriptional regulation 
of liver specific genes. [150]  
These results described above indicate that PPARα and L-carnitine form a 
tight entangled reciprocal signalling system. This theory is also supported 
by the fact, that PPARα itself gets upregulated by L-carnitine as the 
western blot depicted in Figure 35. Further it was reported that PPARα 
plays a key role in the regulation of carnitine homeostasis. It regulates 
genes, which are involved in carnitine synthesis and uptake. [151] 
This close relation between these two compounds leads to the question, 
whether there is direct interaction. It will be the aim of future investigations if 
L-carnitine is able to bind PPARα directly or if other factors are needed for 
interaction. There is evidence that L-carnitine is able to bind directly to 
nuclear receptors like the glucocorticoid-receptor. [115] 
Possible future investigations may also lead into the field of gender 
medicine. As it has been reported, PPARα regulated genes are less 
expressed in females. [152] Since PPARα and L-carnitine showed this tight 
connection also L-carnitine might exert different effects in males and 
females.  
L-carnitine and its possible positive effects in the treatment of Diabetes 
Mellitus Type 2 have been discussed throughout the last decades. As 
mentioned in the introduction (see chapter 1.3) the ratio between free 
acetyl-coA + free L-carnitine and acetylcarnitine + free coA is important for 
regulation of balance of glycolysis and gluconeogenesis. A dysbalance of 
this system leads to increased hepatic gluconeogenesis, one pathologic 
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aspect of Diabetes Mellitus Type II. So shifting this ratio toward 
acetylcarnitine might lead to improved glucose metabolism.  
The importance of CRAT was already shown in human myocytes. 
Overexpression of this enzyme in human skeletal muscle cells increased 
glucose uptake and attenuated lipid-induced suppression of glucose 
oxidation. This implicated that carnitine insufficiency and reduced CRAT 
activity might be reversible components of the metabolic syndrome. [153] 
In the context of L-carnitine and Diabetes Mellitus Type II it was also 
reported that L-carnitine and acetyl-L-carnitine are effective compounds in 
improving insulin-mediated glucose disposal. Glucose uptake and oxidation 
was improved. [154] The authors of this study provided two possible 
mechanisms for this effect: on the one side the regulation of the cellular 
trafficking of acetylcarnitines and acylcarnitines could play a role and on the 
other side the synthesis of glycolytic and gluconeogenetic key enzymes 
were influenced by L-carnitine and acetyl-L-carnitine. 
Here we provide another aspect of the beneficial actions of L-carnitine in 
context of DM Type II and the metabolic syndrome. In previous research 
projects was shown that L-carnitine has a direct influence on the 
transcription rates of many genes throughout the whole genome. Among 
these we find the genes of the acylcarnitine transferase system. Also 
human CRAT and its murine homologue Crat are inducible by L-
carnitine.[132, 141] So administration of L-carnitine leads to increased 
levels of CRAT and provides free L-carnitine. These increased levels of 
CRAT and L-carnitine provide the basis that more acetyl-groups can be 
stored in the acetylcarnitine-pools simultaneously reducing acetyl-coA 
levels. Further more acetyl-coA groups are used in the Krebs cycle and 
gluconeogenesis is reduced.  
This hypothesis would also support the possible influence of fibrates on 
glucose metabolism. Since we provide evidence, that Crat is upregulated 
by fenofibrate. This would implicate that fibrates do not only improve fatty 
acid and lipoprotein metabolism but also may be beneficial in treatment of 
DM Type II and the metabolic syndrome.  
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Appendix 
 
Abbreviations 
 
 
Ab antibiotics 
APS ammoniumpersulfate 
ATP adenosine triphosphate 
BSA bovine serum albumine 
CACT carnitine/ acylcarnitine transferase 
coA coenzyme A 
CPT1 carnitine palmytoyltransferase 1 
CPT2 carnitine palmytoyltransferase 2 
CRAT carnitine acetyltransferase 
CROT carnitine octanoyltransferase 
DMSO dimethylsulfoxide 
DNA desoxyribonucleic acid 
dNTP desoxy nucleotide triphosphates 
DTT dithiothreitol 
EDTA ethylenediaminetetracetic acid 
FCS fetal calf serum 
h hours 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid 
LXR liver X receptor 
mA milliampere 
mg milligram 
MgCl2 magnesiumchloride 
ml milliliter 
mol  
nt nucleotides 
OCTN2 organic cation/carnitine transporter 2 
PATCH attern search program using TRANSFAC 6.0 
PBS phosphate buffered saline 
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PMSF phenylmethanesulfonylfluoride 
PNK polynucleotide kinase 
PPAR peroxisome proliferator-activated receptor 
RXR retinoic X receptor 
SDS sodium dodecyl sulfate 
TBE tris-borate-EDTA buffer 
TEMED tetramethylethylenediamine 
TESS transcription element search system 
TE Tris/EDTA 
TRIS tris(hydroxymethyl)aminomethane 
V volt 
µl microliters 
µM micromolare 
PCR polymerase chain reaction 
RT-PCR real-time polymerase chain reaction 
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Abstract 
 
L-carnitine, an amino acid-like compound synthesized from lysine and 
methionine, is essential for energy metabolism. It mediates the transport of 
long-chain fatty acids prone for ß-oxidation across the inner mitochondrial 
membrane into the matrix. Chip-screen analyses performed in our lab 
revealed that L-carnitine has a distinct regulative effect on the 
transcriptional activity on a significant part of the whole genome (Litzlbauer 
et. al, 2006). Especially the mRNA expression levels of human carnitine 
acyltransferase genes CRAT, CPT1A, CPT2 are regulated by L-carnitine 
(Godárová et al, 2005). We could provide evidence that the murine 
homologues CRAT, CPT1a, CPT2 and OCTN2 are similarly regulated on 
transcriptional level by L-carnitine. qPCR analysis of the murine carnitine 
acetyltransferase (CRAT) gene under supplementation of 80 µM L-carnitine 
for 4 hours resulted in a 2-fold increase on mRNA level. Reporter gene-
assays with constructs carrying different segments of the promoter of the 
murine CRAT gene localized the “carnitine-effect” regulating element within 
a 342bp region. Within this region several putative transcription factor 
bindings sites could be identified with bioinformatical tools. The most 
promising transcription factor binding sites are SP1, PPARα, RXRα and 
CREB. Analysis of the retinoic X receptor alpha (RXRα) element with band 
shift and supershift assays revealed the influence of the transcription 
factors PPARα, LXRα and PPARbP on CRAT gene regulation under 
increasing L-carnitine concentration. Additional Southwestern Blot analysis 
supported the association of these promoter elements to a hypothetical 
transcription factor complex of the RXR locus. qPCR analysis of CRAT 
mRNA expression under PPARα-agonist supplementation supports the 
findings that PPARα is involved in the L-carnitine mediated gene regulation 
of CRAT. This indicates that CRAT gene-expression is a direct 
pharmacological target of these hyperlipidemic drugs.   
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Zusammenfassung 
 
L-Carnitine ist ein semi-essentieller Nährstoff welcher aus den 
Aminosäuren Methionin und Lysin synthetisiert und mit der Nahrung 
aufgenommen wird. Besonders im Energiestoffwechsel erfüllt L-Carnitine 
wichtige Aufgaben. Es ermöglicht den Transport von langkettigen 
Fettsäuren (C16-C18) aus dem Zytosol in die mitochondrielle Matrix, wo 
diese Fettsäuren im Rahmen der β-Oxidation zu Acetyl-CoA abgebaut und 
folglich dem Krebszyklus zugeführt werden.  
L-Carnitine hat jedoch auch einen Einfluss auf die transkriptionelle Aktivität 
von verschiedensten Genen im gesamten Genom. (Litzlbauer et. al, 2006). 
Besonders die Menge an mRNA der humanen Acyltransferase-Gene 
CRAT, CPT1a und CPT2 werden nach Gabe von L-Carnitine hochreguliert. 
(Godárová et al, 2005). In dieser Diplomarbeit war es mir möglich diesen 
Effekt auch in der murinen Leberzelllinie TIB73 nachzuweisen. Durch 
quantitiative Real-Time PCR konnte ein bis zu 2-facher Anstieg der mRNA 
Menge des Gens der Carnitine-Acetyltransferase 4 Stunden nach Gabe 
von 80µM L-Carnitine nachgewiesen werden.  
In Vorarbeiten von Aniko Ginta Pordes konnte mittels Reportergen-Assays 
diejenige Gensequenz eingegrenzt werden welche für diesen „Carnitine-
Effekt“ verantwortlich ist. Diese ist innerhalb von 342nt proximal des ersten 
Exons lokalisiert. Innerhalb dieser Sequenz konnten mittels theoretischer 
Promoteranalyse zahlreiche Bindungsstellen möglicher Transkriptions-
faktoren definiert werden. Darunter fanden sich Consensus-Sequenzen für 
nukleare Faktoren wie Sp1, RXR, PPAR und Creb.  
Mittels MobilityShift Assays wurden diese Kandidaten überprüft. Die 
deutlichsten Effekte wurden bei der Analyse eines RXR Elements 
beobachtet, wobei in Supershift Experimenten besonders nach Gabe von 
PPARα und LXRα Antikörpern ein Abschwächungseffekt ausgemacht 
werden konnte. Der Einfluss von PPARα auf die Regulation der Expression 
des CRAT Gens konnte weiters mittels qPCR nachgewiesen werden, 
nachdem die Gabe von Fibraten zu eindeutigem Ansteigen der 
Expressionslevels von CRAT führte.  
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